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ABSTRACT
COST EFFECTIVE HUMAN PROTEIN C PURIFICATION
FROM COHN FRACTION IV-l USING MINI-ANTIBODY
Doh Gyeuhn Ahn
August 5, 2005
Protein C (PC) is an important anticoagulant, antithrombotic, and antiinflammatory in blood plasma.

PC deficiency can lead to severe venous thrombotic

events, including lung embolism, stroke, and heart attack. In the body, PC is activated
only when it is needed, and, therefore, PC does not cause bleeding problems that
currently available anticoagulants may do.
Purification of PC from plasma

IS

currently done by immunoaffinity

chromatography using monoclonal antibodies (Mabs), which is very expensive. Single
chain variable regions (mini-Mab) with a PC binding capability, which can b(: produced
in recombinant E. coli, were developed for PC purification. Compared to Mabs, miniMabs are easier to control the contamination during the production, with lower
production cost, and easier to scale-up the process. In this Ph.D. research, the effect of
media conditions on the PC mini-Mab production, the mini-Mab purification yield from
the production media, and the PC purification performance of the mini-Mab from Cohn
Fraction IV -1 (an inexpensive PC source) were studied.
The optimum conditions for mini-Mab production medium were detemlined to be
0.1 % glucose, 0.1 mM IPTG, initial pH

5.5~6.0, 23~30

v

°c of media temperature during

the production, and 18 hours of mini-Mab production time.

The final mini-Mab

production level became 450 mg/L.
Mini-Mab in the production medium broth was purified using protein A affinity
chromatography. A purification yield of 34 % was obtained using the elution pH of 3.0.
For PC purification using the PC mini-Mab, among four commercially available
affinity chromatography matrices, NHS Sepharose showed the best performance. The PC
mini-Mab immobilized NHS Sepharose, when Cohn Fraction IV -1 is used as the source
material, showed a PC purification yield of 16 %. High human serum albumin (HSA)
content in the source material was found to reduce PC purification yield significantly.
Therefore, anion exchange chromatography (DEAE) was used for the pretreatment of the
Cohn Fraction IV-I before the affinity chromatography.

DEAE chromatography

removed over 99 % of the human serum albumin from Cohn Fraction IV-I. The PC
purification yield from the eluate of DEAE chromatography of Cohn Fraction IV -1 was
approximately 25 %, increasing by approximately 10 %. PC production cost using the
mini-Mab immobilized NHS-Sepharose matrix was estimated to be approximately 100
times cheaper than that using regular Mab.
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CHAPTER I
INTRODUCTION

Protein C (PC) is a vitamin K dependent glycoprotein in blood plasma.

PC

prevents the blood clotting in the blood vessels (anti-coagulant), dissolves the formed
blood clots indirectly (anti-thrombosis), and prevents inflammation (anti-inflammation)
(Esmon, et aI., 1999).
When a person has a PC deficiency, blood clots may be formed inside blood
vessels and these may cause thromboembolic symptoms, such as, lung embolism, heart
attack, or stroke.
Anticoagulant drugs, such as warfarin (coumarin) and heparin, are used for the
patient who has thromboembolic events. Warfarin is a vitamin K analog and blocks the
production pathway of the vitamin K dependent blood coagulant factors (Hirsh, et aI.,
1998a). However, it frequently causes bleeding problem. Heparin is working as an
anticoagulant catalyzing the inactivation of thrombin and activated human factor IX
(Hirsh, et aI., 1998b).

It may also cause side effects of heparin induced

thrombocytopenia (HIT) and bleeding problem.
In plasma, PC exists as an inactive form (zymogen) at a concentration of 4 Ilg/mI.
It is activated only when it is needed and, therefore, PC does not have the side effects that

warfarin and heparin have.
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The frequency of homozygous and heterozygous PC deficiency together in all the
thrombotic events is 10 %. The other 10 % of thrombosis in the thrombotic events occurs
in people in surgery, pregnancy, oral contraceptive, etc. showing acquired PC deficiency
(Tabernero, et ai., 1991; MaIm, et ai., 1992; Allaart, et ai., 1994).
Currently, from plasma, PC is purified using mouse monoclonal antibody as the
ligand of affinity chromatography. CeprotinTM, human plasma PC purified by the mouse
monoclonal antibody (Mab) against PC (Schoppmann, et ai., 2001), has been licensed in
European countries for patients with a severe congenital PC deficiency (Baxter
International, Inc., 2001). The cost ofCeprotin™ is $78.5 per 100 /-Lg.
To reduce the PC purification cost, single chain variable regions (mini-Mab) of
the Mab against PC was developed by way of phage display method using human V -gene
library (Wu, et ai., 1998b).

Thirteen recombinant E. coli HB2151 colonies, which

produce the mini-Mab against PC, were provided by Dr. Michael Sierks at the Arizona
State University. A preliminary study of the mini-Mab purification, the PC purification
using the purified mini-Mab, and an economic analysis of PC production using mini-Mab
compared with that using Mab were performed by Korah, et al. (2003).
In this dissertation, the results of three different studies are presented:

(1)

optimization of the mini-Mab production condition, (2) optimization of the mini-Mab
purification process, and (3) the PC purification from Cohn Fraction IV -1 using the
purified mini-Mab as ligand of the affinity chromatography.
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CHAPTER II

BACKGROUND

A.PROTEINC
Protein C (PC) is a vitamin K dependent glycoprotein and it is produced in the
liver as the form of zymogen (Stenflo, 1976; Esmon, 1990; Dreyfus, et al., 1991). In
human blood plasma, the typical PC concentration level is 4

~g/ml

and the half-life of PC

in blood plasma is 6-10 hours (Riess, et al., 1985; Miletich, et al., 1987; Okajima et al.,
1990; Dahlback, 1995).

PC is converted to an activated PC (aPC) by thrombin-

thrombomodulin complex at the endothelial cells (Comp, et al., 1980; Marlar, et al.,
1981; Esmon, 1990).

aPC stimulates anti-coagulation by deactivating activated

coagulants, factors V and VIII (Kisiel, et al., 1977). aPC also inactivate plasminogen
activator inhibitor (Marlar, et al., 1982) allowsing tissue plasminogen activator (tP A;
antithrombotic agent) free.

The free tPA converts plasminogen to plasmin and the

plasmin degrades the formed blood clot (de Fouw, et al., 1988).

aPC prevents

inflammation by modulating inflammatory cytokine production and by blocking selectinmediated neutrophil binding (Esmon, 1990). The half-life of aPC in plasma is 15 to 30
minutes (Esmon, 1990).
There are three forms of PC deficiencies, homozygous, heterozygous, and
acquired PC deficiencies. Homozygous PC deficient patients are born with two abnormal
copies of the PC gene (Miletich, et al., 1993).
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Homozygous PC-deficient patients,

usually newborn infants, have very little of the functional PC in blood and, therefore,
have severe thrombosis throughout the body including microvascular thrombosis in brain
and wide spread intravascular coagulation. Without immediate clinical treatment, these
conditions ultimately cause death. The frequency of homozygous PC deficiency is about
1 in 250,000 to 500,000 births (Marlar, et aI., 1990).
Heterozygous PC deficiency patients are born with a lower concentration of PC
than that of normal people (Type 1) or with an abnormal copy of the PC gene (Type 2).
Heterozygous PC-deficient patients are at risks of venous thrombotic events, including
deep vein thrombosis, pulmonary embolism, stroke, and heart attack. Although they are
not as urgent cases as those with the homozygous PC deficiency, the heterozygous PC
deficiency exhibits symptoms in most individuals before 30 years of age (Sills, et aI.,
1984; All aart , et aI., 1995). The frequency of heterozygous PC deficiency is 0.1 to 0.5
percent of the general population (Miletich, et aI., 1993).
Each year, approximately 1 in 1,000 people, who do not have any genetic PC
deficiency, at the age of 20 and 50, are affected by venous thrombosis (Goldhaber, et aI.,
1994). 3-10 % of these groups have a lower PC concentration level than the normal
(Makris, et aI., 1997; Heijboer, et aI., 1990).

These acquired PC deficiencies are

associated with surgery, pregnancy, the use of oral contraceptives, Coumarin therapy,
liver diseases, or body immobilization (Makris, et aI., 1997; MaIm, et aI., 1992;
Tabernero, et aI., 1991; Allaart, et aI., 1994).
Successful treatments for homozygous PC deficient patients using fresh-frozen
PC-containing plasma have been reported (Marlar, et aI., 1990; Dreyfus, et aI., 1991).
Frequent infusions of the fresh-frozen plasma, however, result in hyperproteinemia (Sills,

4

et aI., 1984). CeprotinTM, human plasma PC concentrate without other clotting proteins
has been licensed in European countries recently (Baxter International, Inc., 2001).
Ceprotin™ is for purpura fulminans and coumarin-induced skin necrosis in patients with
a severe congenital PC deficiency. Ceprotin™ costs approximately $80 per 100 Ilg.
Activated PC can be used also for the treatment of sepsis, which is the systemic
response to severe bacteria infection in the blood and is associated with multiple organ
dysfunctions (Bone, et aI., 1997). Sepsis has been reported as the leading causes of death
in surgical intensive care units. Approximately 750,000 cases of sepsis occur in the
United States each year (Bernard, et aI., 2001). The mortality rate of severe sepsis is
approximately 20 % within 6 months (Rangel-Frausto, et aI., 1995).

Recently, a

recombinant human activated PC, XigrisTM, has been approved by the US Food and Drug
Administration (FDA) to treat sepsis (Eli Lilly, 2001). The average wholesale prices of
the 5 mg and 20 mg Xigris ™ are $210 and $840, respectively.
recommended 96-hour dose

(~0.2

The price for the

g) is $7,700.

Therefore, it is very important to provide cheap PC to PC-deficient patients,
sepsis patients, patients having various thrombo-embolic episodes.

B. PC SOURCES
Currently available PC sources are human blood plasma (Schwarz, et aI., 1990),
mammalian cell culture medium (Grinnell, et aI., 1990), and transgenic pig milk
(Velander, et aI., 1992; Dalton, et aI., 1997). Human blood plasma is a natural source and
has less immunogenic reactions in the human body. The production level of recombinant
human PC (rhPC) from mammalian cell culture medium was reported to be 20 to 30
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Ilg/ml/l06 cells/day from adenovirus transformed human kidney 293 cell lines (Grinnell,
et aI., 1990). The rhPC production level in transgenic pig milk was reported at 380 Ilg/ml
per hour from the mammary gland of a pig (Velander, et aI., 1992). However, the total
recovery is only 24 % and PC production from transgenic pig milk requires many steps
and large quantities of precipitation agents like polyethylene glycol (Wu, 2000; Wu, et
aI.,2002).
Commercially available cheap human plasma derived Cohn fraction IV -1 can be
used as a volume reduced and enriched starting materials for producing pure PC
(Vel ander, et aI., 1990).
Cohn, et aI. have developed a method to fractionate many blood plasma proteins
on a large scale, which were required in wartime (Creager, 1999). It was based on
changing the solubility of the proteins using different pH values, temperatures, and
ethanol concentrations. The plasma proteins were separated into five major fractions
(Cohn, et aI., 1946): as much as possible of fibrinogen in Fraction I, y-globulins in
Fraction II, lipid-bearing

~-globulins

in Fraction III, a-globulins in Fraction IV, and

albumins in Fraction V. To separate the proteins effectively, several methods were tried
changing the ethanol concentration and pH (Figure 1).

Cohn Fraction IV -1 is a

byproduct of human serum albumin fractionation of blood plasma and usually discarded
(Cohn, 1948).
The Cohn Fraction IV -1 is known to include over 90 % of PC in Plasma, and
coagulating factors, such as factors II, VII, IX, and X (Velander, et aI., 1990; Wu, et aI.,
1998a).
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Figure 1. Schematic diagram of Cohn Fractionation.

C. METHODS USED FOR THE PURIFICAnON OF PC FROM PLASMA
1. Immuno-Affinity Chromatography
Although human blood plasma and its derivatives are good sources of PC, they
contain several proteins homologous to PC. Many of these homologues are coagulants,
such as, Factors II, VII, IX and X (Foster, et aI., 1985; Furie, et aI., 1988; Leytus, et aI.,
1986; Yoshitake, et aI., 1985). Traditional chromatography methods other than immunoaffinity method, therefore, may not be employed for PC purification.

PC has been

purified using immuno-affinity chromatography (Nakamura, et aI., 1987; Schoppmann, et
aI., 2001; Schwarz, et aI., 1990).
Nakamura, et aI. (1987) produced monoclonal antibodies and obtained 59.3 % of
PC recovery by immunoaffinity chromatography. They reported also that 70 % of PC
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was adsorbed on their monoclonal antibody using commercially available prothrombin
complex concentrate, an eluate of anion exchange chromatography of human blood
plasma in single step purification (Nakamura, et aI., 1987).
Velander, et aI. (1990) have reported PC purification from an eluate of DEAE
anion exchange chromatography of reconstituted Cohn Fraction IV-I. 2 mg of IgG was
immobilized on 1 ml matrix. Using approximately 40 ml of the reconstituted Cohn
Fraction IV -1 and 4 ml of the matrix, 25 % overall recovery of PC was obtained using
direct immunopurification (Velander, et aI., 1990).
Kang, et ai. (1992) developed a method for estimating the immunoaffinity PC
purification performance using an affinity chromatography to estimate both the time and
the cost of a large-scale PC purification process.

The points to consider the mass

production of PC are Mab adsorption efficiency on gel matrices, adsorption efficiency of
PC to the immobilized Mab, and the specific activity of the eluted PC. In addition, it was
reported that for the scale up of PC purification processes, pressure tolerance of the gel
matrices and production rate should be considered.

2.IMAC
The cost of Mab production using animal cell culture is very high. Hence, PC
purified using Mab is very expensive.

Therefore, a much cheaper method than

immunoaffinity chromatography, immobilized metal affinity chromatography (IMAC),
was investigated to purify PC from Cohn Fraction IV -1 (Wu, et aI., 1998a; 1999).
PC purification from prothrombin, a major coagulant factor in plasma, was
studied using the mixture ofPe and prothrombin. IDA- copper ion was used and 95.5 %
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of active PC was effectively recovered (Wu, et aI., 1999). Therefore, it was reported that
copper IMAC may be cost effective method to purify PC from prothrombin instead of
using immunoaffinity chromatography.
For the PC purification from Cohn Fraction IV-l using iminodiacetic acid (IDA)
and copper ion, 84 % of PC recovery was obtained (Wu, et aI, 1998a). However, the
eluate included many contaminants based on gel electrophoresis, indicating that PC in
Cohn Fraction IV -1 may not be separated by one step IMAC process (Wu, 2000)

D. PC HOMOLOGUES
Vitamin K dependent homologous proteins are factors II, VII, IX, and X as well
as PC, protein S, and protein Z and all are produced in liver (Broze, et aI., 1984). Factors
II, VII, IX, and X playa key role in blood clotting (Kisiel, et aI., 1977; Marlar, et aI.,
1982; Esmon, 1990). Protein S is acting as a cofactor of the activated PC to enhance the
inactivation of the activated factor V and VIII (Griffin, et aI., 1999).

Protein Z is

considered to suppress thrombus formation inhibiting the activated factor X (McQuillan,
et aI., 2003).
The properties of vitamin K-dependent proteins were compared in Table 1. The
molecular weights and the isoelectric points of the proteins are closely distributed at the
range of between 50,000 and 72,000 kDa and between 4.0 and 5.5, respectively.
Therefore, the separation of PC from these homologous proteins is a challenge.
After separation of PC, several methods including gel electrophoresis, enzyme
linked immunosorbent assay (ELISA), and the activity test may be required to
characterize the purified PC.
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Table 1. Properties of vitamin K-dependent proteins.

Proteins

Molecular
Weight

Function

Conc.
in
plasma
(J,lg/ml)

Half
life in
plasma
(hours)

Level
Required
for
Hemostasis

Isoelectric
point

6-10

>60%

Extinc.
Coeffi.
(1%
)

Reference

4.4 - 4.8

14.5

[24], [28], [33],
[56], [66]

>50%

5.0 - 5.5

9.5

[24], [28], [33],
[56]

Elcm,280nm

Protein C

62,000

Anticoagulant

3.9-5.9

Protein S

69,000

PC cofactor

20-35

Protein Z

62,000

-

2.9

60

-

-

12.0

[19], [24], [60]

Factor II

72,000

Coagulant

80-90

48-120

20-40 %

4.7-4.9

13.8

[24], [33], [34],
[54], [56]

Factor VII

50,000

Coagulant

0.47

4-7

10-20 %

13.9

[8], [17], [24],
[33], [56], [100]

Factor IX

57,000

Coagulant

4-5

20-24

25-30 %

4.0-4.6

13.2

[24], [33], [34],
[56], [91]

Factor X

59,000

Coagulant

6.4

24-40

10-20 %

4.8 - 5.0

11.6

[24], [33], [34],
[55], [56]

15

(rabbit)

4.8- 5.1

(bovine)

E. MINI-ANTIBODY SPECIFIC AGAINST PC
Immunoglobulin (IgG) is produced from B cell in the spleen and consists of four
polypeptide chains (Figure 2).

In an IgG molecule, two heavy chains and two light

chains are held together by disulfide bonds. The antigen-binding site is at the amino end
of each variable fragment (Lu, et aI., 1996). The antigen recognition region consists of
one variable region in one heavy chain (V H) and one variable region in one light chain

The heavy chain and light chain V -genes are shuffled at random and cloned for
displaying as single chain variable fragments (scFvs) on the surface of filamentous phage
to make the phage antibody library containing V -genes, and the phage-antibody
fragments of the library are selected by binding to antigen. In addition, scFv with high
specificities of binding to human self-antigens can be made from the same phage library
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Mini-antibody
(30 kDa)

Antigen binding sites ~

Fv

Fab

(150 kDa)

Fe

Figure 2. Structure ofMab.

(Griffiths et aI., 1993; Marks, et aI., 1991). The mini-Mab against PC in this study was
developed using the same V -genes (Wu, et aI., 1998).
The phage library including V -genes specific to PC is isolated by a two-step
selection procedure from the library (Wu, et aI., 1998b).

First, undesired coagulant

factors, Factor IX or Factor X, which are homologous proteins to PC, are coated on a
solid support - a micro titer plate used for enzyme linked immunosorbent assay (ELISA).
Advantages of producing mini-Mabs using the recombinant E. coli compared with
Mabs include less contamination problems during production, less shear sensitivity of the
host cell, less expense, and easier scale-up.
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F. PREVIOUS STUDY ON PC PURIFICATION USING MINI-MAB
Mini-Mab purification and PC purification using PC mini-Mab were initiated by
Wu, et al. (1998b). Korah, et al. (2003) carried out preliminary, quantitative studies on
mini-Mab purification and PC purification using the purified mini-Mab. The following
studies were performed by Korah.
Mini-Mab Production and Purification. The concentration of IPTG as an inducer
in the mini-Mab production media was optimized from 1 mM to 0.1 mM. Mini-Mab was
purified from the protein A immobilized CNBr-Sepharose chromatography. The 18 % of
mini-Mab purification efficiency was obtained using an elution pH 3.0 of the glycine
buffer. The metal ions of IMAC have affinity to histidine, cysteine, and tryptophan.
Mini-Mab may contain these metal ion binding residues on the amino acid side chains of
its surface.

Therefore, mini-Mab purification was tested using IMAC column.

The

commercially available HiTrap Chelating IMAC column with a pre-immobilized chelator
was used. Metal ions such as Ni 2+, Cu2+, C02+, and Fe2+ were applied to the column.
Cu2+ and C0 2+ were leached out during the mini-Mab adsorption at pH 7.4. Fe-IMAC
showed only 0.3 % ofmini-Mab purification yield at pH 7.4. When Ni-NTA was used at
pH 6.4, using the purified mini-Mab, 40% ofmini-Mab purification yield was obtained.
PC Purification. PC purification using the pure sample was performed on miniMab immobilized gel matrices. CNBr activated sepharose and monoaldehyde-agarose
(Actigel™ ALD) matrices were tested. Immobilization efficiency showed approximately
80 % and 45 % for the CNBr activated sepharose matrix and Actigel, respectively. PC
purification efficiency using the CNBr activated sepharose and the Actigel showed
approximately 6 % and 10 %, respectively.
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Economic Analysis of PC Production. PC production cost using between miniMab and Mab, Korah (2003) were compared in terms of the costs of antibody production,
antibody purification, and PC purification. The specific production cost of mini-Mab was
evaluated 500 times lower than that of Mab's. Based on mini-Mab purification using
IMAC column, the yield ofMab purification (70 %) was evaluated 1.75 times higher than
mini-Mab's (40 %; Korah, 2002). PC purification yield using Mab (70 %) was evaluated
7 times higher than mini-Mab's (10%). Based on the date obtained from the antibody
production, antibody purification, and PC purification, Korah estimated that PC
purification using the mini-Mab is 40 times cheaper than using regular Mab.
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CHAPTER III
MATERIALS, INSTRUMENTS, AND METHODS

A. MATERIALS

1. Mini-Mab Production
Thirteen recombinant E. coli HB2151 colonies that contain the PC mini-Mab
producing gene were provided by Dr. Michael Sierks at the Arizona State University.
The E. coli culture media was made using Trypton, NaCI, glucose, phenylmethylsulfonyl
fluoride (PMSF), ampicillin (Sigma-Aldrich, Inc.; St. Louis, MO), and yeast extract
(Bacto Laboratories; Liverpool, Australia). Isopropyl P-D-thiogalactopyranoside (IPTG;
ICN Biomedical, Inc.; Irvine, CA) was added into the production media to induce the
mini-Mab expression. Lactose was added (Sigma-Aldrich, Inc.) and sucrose, Triton X100, and phopholipase A2 (Sigma-Aldrich, Inc) for the study of mini-Mab release from
E. coli cells. E. coli cells were separated by a centrifuge in centrifuge tubes (Greiner Bio-

one; Longwood, FL).

The supernatant was concentrated using Centricon, a 19 ml

ultrafiltration filter (Millipore; Schwalbach, Germany).

2. Mini-Mab Purification
Protein A immobilized CNBr-activated Sepharose™ CL-4B (Protein A
Sepharose TM), glycine, and citric acid were purchased from Sigma-Aldrich.

Glass

Econo-Column® chromatography column (Bio-Rad; Hercules, CA) was used to pack the
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gel matrix.

Slide-A-Lyzer® Dialysis Cassette (Pierce; Rockford, IL) with 10,000 Da

molecular weight cut off was used for the buffer dialysis.

3. PC Purification
PC and Cohn Fraction IV -1 paste were provided by the American Red Cross
(Rockville, MD) and human blood factors II, VII, IX, and X were purchased from
Innovative Research, Inc. (Southfield, MI).

Normal hydroxysuccinimide (NHS)-

activated Sepharose ™ 4 Fast Flow (NHS Sepharose TM) and diethylaminoethyl (DEAE)
Sepharose™ Fast Flow (DEAE Sepharose™) were purchased from Amersham
Biosciences (Piscataway, NJ).

Actigel ALDTM (ActigeI™) and Epoxy Activated

Ultraflow 4™ (Epoxy Activated™) were from Sterogene (Carlsbad, CA). A Supor®,
membrane filter papers with 47 mm diameter and 0.2, 0.45, and 0.8 /lm pore sizes were
obtained from Gelman Sciences (Ann Arbor, MI) to filter buffer and Cohn paste solution.

4. Gel Electrophoresis
Tris base, lauryl sulfate, glycerol, bromophenol blue, methanol, Brilliant Blue R,
acrylamide solution, ammonium persulfate, tetramethylethylenediamine (TEMED) and
acetic acid (Sigma-Aldrich) were used for the sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE). SigmaMarker™ standard molecular marker (SigmaAldrich; myosin, 205 kDa;

~-galactosidase,

116 kDa; phosphorylase b, 97 kDa; fructose-

6-phosphate kinase, 84 kDa; bovine serum albumin, 66 kDa; glutamic dehydrogenase, 55
kDa; ovalbumin, 45 kDa; glyceraldehyde-3-phosphate dehydrogenase, 36 kDa; carbonic
anhydrase, 29 kDa; trypsinogen, 24 kDa; trypsin inhibitor, 20 kDa; a-lactalbumin, 14.2
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kDa; and aprotinin, 6.5 kDa) was used for the comparison of the molecular weights of
proteins on the SDS-PAGE.

5. Enzyme Linked Immunosorbent Assay (ELISA)
96 well microtiter plates (Nalgen Nunc International; Roskilde, Denmark) were
used for ELISA for the measurement of the concentrations of the mini-Mab, PC, vitamin
K dependent coagulation factors, and human serum albumin (HSA).

2-amino-2-

(hydroxymethyl)-1,3-propanediol (Tris base), NaHC0 3, Na2C03, phosphate buffered
saline (PBS), Tween 20, horseradish peroxidase-conjugated goat anti mouse IgG,

0-

phenylenediamine dichloride (OPD) solution containing urea hydrogen peroxide, human
serum albumin, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich.
For the mini-Mab ELISA, anti-c-myc antibody (9E10) was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). For the ELISA of PC and the other factors, Rabbit
polyclonal factor II antibody was purchased from Biomeda Corporation (Foster city, CA)
and mouse monoclonal factor II antibody, from Enzyme Research Laboratories (South
Bend, IN). Rabbit polyclonal factor VII antibody was obtained from Novus Biologicals,
Inc. (Littleton, CO), and goat polyclonal factor X antibody and goat polyclonal human
serum albumin antibody, from US biological (Swampscott, MA). Mouse monoclonal
human serum albumin antibody was purchased from Biodesign International (Saco, ME).
Rabbit polyclonal antibodies for PC and factor IX, mouse monoclonal antibodies against
PC and factors VII, IX, and X were obtained from Sigma-Aldrich.
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6. Protein Assay
The total protein was quantified using Bicinchoninic Acid (BCA *TM) protein
assay reagents from Pierce (Rockford, IL).
All other chemicals, unless otherwise specified, were purchased from SigmaAldrich.

B. INSTRUMENTS
1. Mini-Mab Production
Antibodies, E. coli cell lines, and purified samples were stored in a -70°C freezer
(Resco; Ontario, Canada). An autoclave (Sterilmatic; Market Froge; Everett, MA) was
used to sterilize the media by heat or a disposable sterile syringe filter (Coming Glass
Works; Coming, NY) was used to sterile the media. A laminar hood (Purifier Class II
Biosafety Cabinet; Labconco Corporation; Kansas City, MO) was used for the control of
contamination while the E. coli cells are inoculated in the media. E. coli was cultured in
a shaking incubator (C24 incubator shaker; New Brunswick Scientific; Edison, NJ).
Accumet pH Meter (Fischer Scientific; Pittsburgh, PA) was used to measure the pH. E.
coli cell density and the protein concentration were measured using a DU SERIES 500

Spectrophotometer (Beckman Instruments, Inc.; Fullerton, CA). The produced mini-Mab
and the purified PC were quantified using an ELISA plate reader (Bio-Rad; Hercules,
CA). The incubation temperature for protein quantification and ELISA was controlled in
Isotemp Incubator (Fischer Scientific).
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2. Mini-Mab and PC Purification
A Marathon 3200

®

general-purpose centrifuge (Fischer Scientific) was used for

E. coli cell separation and the ultra-filtration. The purification of the mini-Mab and PC is
performed using FRAC-100 (Amersham Biosciences; Piscataway, NJ) and its
accessories, peristaltic pump P-1, Control Unit UV -1, Optical Unit UV -1, and the
recorder REC 101. Chromatography columns were purchased from Bio-Rad (Hercules,
CA). SDS-PAGE was carried out using a Mini-Protean 3 Celli PowerPac Basic System
(Bio-Rad) and its accessories, combs, plates, and casting accessories for 10-well.

C.METHODS
1. Mini-Mab Production

Culture media for the E. coli cell growth and mini-Mab production were prepared.
2XTY media (Trypton: 16 gil; yeast extract: 10 gil; NaCl: 5 gil) was autoclaved at 121°C
for 20 minutes. Glucose stock solution at a concentration of 200 gil was filtered using
syringe filters of 0.45

~m

pore size (Coming Glass Works; Coming, NY), and applied to

a flask to adjust the final concentration of 1% for the cell growth media and 0.1 % for the
mini-Mab production media. Ampicillin stock solution at a concentration of 100 mglml
was applied to the media to make the final concentration of 100

~g/ml.

The compositions of the cell growth and the mini-Mab production media are as
follows:
(1) Cell growth media: 2XTY media, 1 % glucose, and 100

~g/ml

of ampicillin.

(2) Mini-Mab production media: 2XTY media, 0.1 % glucose, 100
and 1 mM oflPTG.
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~g/ml

of ampicillin,

E. coli colonies from the cell stock were added to the cell growth media and
cultured at 37°C in a shaking incubator at 300 rpm. When the optical density (O.D.) of
the culture media reached 0.9 at the wavelength of 600 nm, the cells were separated using
a centrifuge at 4000 rpm for 20 minutes. The separated cells from the cell growth media
were transferred to the mini-Mab production media and cultured in the shaking incubator
at 300 rpm for 24 hrs at 30°C. After the mini-Mab production, cells were separated
using the centrifuge at 4000 rpm for 20 minutes. The concentration of mini-Mab in the
supernatant is measured using ELISA. To make the E. coli cell stock, E. coli cells were
grown in the cell growth media until the optical density (O.D.) of the media becomes 0.9,
and the E. coli cells were separated using the centrifuge at 4000 rpm for 20 minutes. The
separated cells were transferred to 20% glycerol solution in the laminar hood and stored
in a deep freezer (-70°C). Whenever needed, the E. coli cell stock was thawed and
inoculated to the media in the laminar hood.

2. Mini-Mab Purification
The mini-Mab in the production media supernatant was purified using Protein A
Sepharose™ following the manufacturer's instruction. Protein A Sepharose™ matrix
was suspended with 0.02 M NaHzP04-0.15 M NaCl solution (PH 8.0) overnight at 4°C to
swell. The matrix was degassed using vacuum pump for an hour at 200 mm Hg. The
matrix suspension was transferred into a chromatography column and was allowed to
settle for an hour. Then, it was washed with 20-bed volumes of 0.02 M NaHzP04-0.15 M
NaCl solution.
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After the protein A column is prepared, the supernatant from the production
media was applied into the column at the linear velocity of 0.015 cm/s.

After the

adsorption process is completed, any unbound protein was washed using 0.02 M
NaHzP04 -O.15 M NaCl solutions until the UV reading reached the base line. The bound
mini-Mab was eluted with 0.1 M glycine buffer (pH 3.0) or 0.1 M citric acid buffer (pH
3.0). Fractions were collected, and neutralized with 0.1 M NaOH. The column was
washed with 20-bed volume of 0.02 M NaHzP04 -O.15 M NaCl solution following 0.5 M
NaCl solution.

The column was re-equilibrated with 20-bed volume of 0.02 M

NaH zP0 4-O.15 M NaCl solutions for the next use. The amounts of the mini-Mab in the
supernatant, eluted fractions, and other solutions were measured using ELISA.

3. PC Purification

Actigel ALDTM matrix.

Mini-Mab coupled Actigel™ matrix was prepared

following the manufacturer's instruction. Approximately 1 ml of the matrix was applied
to a sintered glass filter and washed with 3-bed volumes of 0.1 M PBS buffer (coupling
buffer; pH 6.9).

The gels were suspended with 1 ml of the coupling buffer.

Predetermined amount of the mini-Mab in coupling buffer was added to the gel
suspension.

1 M NaCNBH3 (coupling solution) was added to the gel suspension and

mini-Mab mixture at the final concentration of 0.1 M. The total volume of the mixture
was adjusted to 3.5 ml with 0.1 M PBS buffer. The coupling reaction was performed by
a shaking incubator at 100 rpm and 30°C for 5 hours. After coupling, the supernatant
was removed using a sintered glass filter with 150 micron of pore size.
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The matrix was washed with 3 bed-volume of adsorption/washing buffer (0.02 M
sodium citrate-0.08 M NaCI at pH 6.0) following washing with 10-bed volume of 0.5 M
of NaCI to remove non-covalently bound mini-Mab from the matrix. The filtrate was
used to calculate the coupling yield. It was then degassed under vacuum for an hour at
200 mm Hg. The gels were packed in a column. The matrix was equilibrated with lObed volume of 0.02 M sodium citrate-0.08 M NaCI (pH 6.0).
0.02 M sodium citrate-0.08 M NaCI at pH 6.0 (adsorption/washing buffer) and 0.1
M sodium carbonate buffer-O.l5 M NaCI at pH 10.0 (elution buffer) were chosen for PC
purification following the PC purification protocol of Kang, et al. (1992). When the
column for the PC purification was ready, 20

~g

of pure PC was applied to the column.

10 minutes was allowed for satisfactory adsorption reaction.

The column was then

washed withl0-bed volume of adsorption/washing buffer at the linear velocity, 0.015
cm/s. After the washing was complete, the elution buffer was applied at the velocity of
0.015 cm/s until the UV reading returned to the base line. The pH of the eluted PC was
immediately neutralized by adding 3.0 M HCl. The column was then washed with the
10-bed volume of adsorption/washing buffer and 0.5 M NaCl following the 10-bed
volume of adsorption/washing buffer.
NHS-activated Sepharose™ 4 Fast Flow.

Coupling of the mini-Mab was

performed by the manufacturer's instruction. 1 ml ofNHS-activated Sepharose™ 4 Fast
Flow (NHS Sepharose TM) matrix was washed on a sintered glass filter with 10 ml of 1
mM HCI at 4°C. The matrix was suspended in 10 ml of 0.2 M NaHC0 3-O.5M NaCI (PH
8.2; coupling buffer). Immediately afterwards, predetermined amount of the purified
mini-Mab was added to the matrix suspension. The total mixture volume was adjusted to
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6 ml. Incubation was performed by a shaking incubator at 100 rpm and 30 °c, for 5
hours. After coupling, the supernatant was removed and 6 ml of 0.1 M Tris-HCI (pH 8.0;
blocking buffer) was added to the matrix, was reacted for additional 4 hours at room
temperature. The matrix was packed in a chromatography column. To remove the noncovalently bound mini-Mab, the gel in the column was washed with 25-bed volumes of
each PBS buffer (PH 7.3), PBS-l M NaCI, cold water, 0.1 M Na2C03-0.5 M NaCI (pH
11), 0.1 M sodium acetate (0.5 M NaCI; pH 4), 0.1 M Na2C03-0.5 M NaCI (PH 11), 0.1
M sodium acetate (0.5 M NaCl; pH 4) and again PBS respectively.

The mini-Mab

amount in the filtrate was quantified by ELISA to obtain the coupling efficiency.
Epoxy Activated Ultraflow™. Mini-Mab coupled Epoxy Activated Ultraflow™
matrix was prepared following the manufacturer's instruction. Approximately 1 ml of
the gel matrix was applied to a sintered glass filter and washed with 5 ml of deionized
(DI) water. Predetermined amount of the mini-Mab was dissolved in 2 ml of 0.1 M
sodium phosphate buffer (pH 10; coupling buffer). The pre-washed matrix was added to
the mini-Mab solution. The solution of the matrix and mini-Mab was mixed in a shaking
incubator at 100 rpm and 25°C, for 18 hours.

After coupling, the supernatant was

removed and 1.5 ml of 50 mM of ethanolamine (pH 8.5; blocking buffer) was added to
the complex of the mini-Mab and the matrix and reacted for additional 4 hours at room
temperature. To remove the non-covalently bound mini-Mab, the gel in the column was
washed with 25-bed volumes of DI water and 3-bed volumes of adsorption/washing
buffer (0.02 M sodium citrate-0.08 M NaCI at pH 6.0) following washing with la-bed
volume of 0.5 M of NaCl. The gel matrix was equilibrated with la-bed volume of the
adsorption/washing buffer.
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4. ELISA
ELISA for the mini-Mab guantification.

The ELISA protocol was originally

developed by Wu, et al. (1998) and optimized by Korah, et al. (2003).
The washing buffer used for this assay is phosphate buffered saline with 0.05%
Tween 20 (PBST, 0.01 M PBS, 0.138 M NaCI, 0.0027 M KCI, pH 7.4),
dilution/adsorption buffer was PBS, and the blocking buffer was PBST with 1 % BSA.
(1) Coat each well of a 96 well plate with 100

~l

of PC at a concentration of 1

~g/ml

in

adsorption buffer except the first column (control).
(2) Incubate the plate overnight at 4 DC.
(3) Wash each well with the PBS buffer (250
(4) Apply the blocking buffer (250

~l/well)

~l/well)

three times.

in each well and incubate the plate for 90

minutes at room temperature.
(5) Wash each well with the washing buffer three times.
(6) Apply 100

~l

of the dilution buffer to all wells except the wells on the first (control)

and the second columns. Apply 200

~l

of the mini-Mab standard, as well as the

samples, to the respective rows in the second column and perform a liz serial dilution.
(7) Incubate the plate at room temperature for two hours.
(8) Wash each well with the washing buffer three times.
(9) Apply 100

~l/well

of 9E 10 antibody at a concentration of 1

except first column.
(10) Incubate the plate for two hours at room temperature.
(11) Wash each well with the washing buffer three times.
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~g/ml

in PBS to all wells

(12) Prepare horseradish peroxidase (HRP) conjugated goat anti-mouse IgG at a 1: 1000
dilution in PBS and add 100

~l/well.

(13) Incubate the plate for 30 minutes at room temperature.
(14) Wash each well with each washing buffer and PBS three times respectively.
(15) Add 100

~l/well

of OPD solution.

(16) Incubate the plate in a dark room for 30 minutes at room temperature.
(17) Read the absorption of the wells at 450 nm using the ELISA plate reader. Calculate
the concentration of the mini-Mab in the sample using the standard.

ELISA for quantification of PC and other factors.

ELISA was based on the

protocol developed by many researchers (Boyer, et aI., 1984; Soria, et aI., 1985; Suzuki,
et aI., 1985) and this ELISA protocol was optimized by the American Red Cross (Wu,
2000b).
The washing buffer used for this assay is Tris buffered saline (TBS, 12.5 mM Tris
buffer, 0.05 M NaCl, pH 7.2) with 0.05% Tween 20 (TBST), dilution buffer was TBS,
and the blocking buffer was TBS with 0.1 % BSA for the PC and other factors or 4 % fish
serum for human serum albumin.

Buffer for adsorption on the wells was 0.1 M

NaHC03/Na2C03 at pH 9.6.
(1) Coat the wells with 100

~l

of the polyclonal antibody against the factor in the

adsorption buffer at the concentration of 2

~g/mI.

(2) Incubate the plate overnight at 4°C.
(3) Wash each well with the washing buffer (250
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~l/well)

three times.

(4) Block each well with the blocking buffer (250 Ill/well) for 90 minutes at 37°C in an
incubator.
(5) Wash each well with the washing buffer three times.
(6) Apply 100 JlI of the dilution buffer to all wells except the wells on the first (control)
and the second columns. Apply 200 III of PC or other factors as standard, as well
as the samples, to the respective rows in the second column and perform

~

serial

dilutions.
(7) Incubate the samples at 37°C in an incubator for 90 minutes.
(8) Wash each well with the washing buffer three times.

(9) Apply 100 Ill/well of the mouse monoclonal antibody for the respective factor at a
concentration of 1 Ilg/ml.
(10) Incubate the plate for 90 minutes in an incubator at 37°C.
(11) Wash each well with the washing buffer three times.
(12) Prepare goat anti-mouse IgG peroxidase conjugate at a 1: 1000 dilution in the
dilution buffer and add 100 Ill/well.
(13) Incubate the plate at room temperature for 30 minutes.
(14) Wash each well with the washing buffer at least six times.
(15) Add 100 Ill/well of the OPD solution.
(16) Incubate the plate in a dark room at room temperature for 30 minutes.
(17) Read the absorption of wells at 450 nm using an ELISA plate reader. Obtain the
concentration of PC or other factors in the sample using the standard.
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5. Protein Assay
Bicinchoninic Acid (BCA *TM) protein assay was used to quantify the total protein
in the sample. A 100 /-!l of protein sample was added to 2 ml of the BCA *™ Protein
Assay Reagent. The solution was mixed and was incubated at 37°C for 30 minutes.
After the incubation, the solution was cooled to room temperature for an hour, and the
absorbance was measured at 562 nm.

From the optical density of the sample, the

concentration of protein was calculated using BSA as a standard.
Purified mini-Mab can be optically quantified using a spectrophotometer reading

O.D. at 280 nm.

The extinction coefficient of variable light chain of human

Immunoglobulin G (IgG) was known to be E~81~m=1.16 (Fasman, 1989) but the
extinction coefficient of the mini-Mab is not known.
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Figure 3. Standard curve for the purified mini-Mab concentration. BSA
was used as a reference material for BCA protein assay. The incubation
temperature and time were 37 DC and 30 minutes respectively.
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Therefore, the amount of the mini-Mab by the BCA *™ was correlated with the
spectrophotometer reading at 280 for the purified mini-Mab (Figure 3). The extinction
coefficient of the mini-Mab was estimated as E ~l~m =0.94.

6. SDS-PAGE
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-P AGE) was
performed following the manufacturer's instruction. The separation gel was made with
30% acrylamide solution, 20% ammonium per sulfate, water, TEMED, and Tris HCl
buffer at pH 8.8. The protein was denatured in SDS solution at 100°C for 5 minutes.
Once the gel is ready, the 20 III of each sample and the molecular marker were applied to
wells respectively. The amount of protein sample in each well was at least 1 Ilg. The
molecular weight was obtained by comparing the positions of the molecular markers that
shows bands of known molecular weight.

7. Pretreatment of Cohn Fraction IV -1 for the PC Purification
The preparation of Cohn Fraction IV -1 sample was carried out based on the
protocol by Wu (2000) with the modifications of the centrifugation speed using 4000 rpm
instead of using 8000 rpm and dilution ratio of Cohn paste to buffer at 1 to 20 instead of
at 1 to 30. The Cohn paste was dissolved in sodium citrate buffer (PH 6.0) at a ratio of 1
to 20 (weight to volume ratio) at 4 °c for 5 hours with constant stirring using a magnetic
stirrer. Then the solution was centrifuged at 4000 rpm for 20 minutes and the supernatant
was filtered using three filters with different pore sizes, such as, 0.8, 0.45, and 0.2 11m,
respectively, which were found to be effective to filter the Cohn Fraction IV -1 solution
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by Lee in our lab. The filtrate was used as the source material for the PC purification
using the mini-Mab.

8. Ion Exchange Chromatography of Cohn Fraction IV-l Using DEAE Sepharose™ Fast
Flow
Following the manufacturer's instruction, DEAE Sepharose™ Fast Flow (DEAE
Sepharose TM) matrix was prepared. Approximately 1 ml of the gel matrix was applied to
a sintered glass filter and washed with 5 ml of deionized (DI) water and degassed for one
hour, and packed in a chromatography column. Then, the matrix was equilibrated with
IO-bed volumes of 25 mM sodium citrate buffer (pH 6.0). Approximately 20 g of Cohn
Fraction IV -1 was dissolved into 400 ml of 0.02 M sodium citrate buffer at pH 6.8 at 4 °c
with magnetic stirring for approximately three hours. The Cohn Fraction IV -1 solution
was then centrifuged at 4000 rpm for 20 minutes. The supernatant was adjusted to pH
6.0 and then applied to the DEAE Sepharose ™ at a flow rate of 0.004 cm/s. The column
was then washed with 0.025 M sodium citrate buffer (pH 6.0) using 50-bed volumes.
The column was then washed with 20 column volumes of 0.02 M 4-morpholineethanesulfonic acid (Mes) including 0.17 M NaCI (pH 6.0) using about I50-bed volumes.
Then, the fractions were eluted by 3- to 4-bed volumes of elution buffer including 0.02 M
Mes and 0.37 M NaCI at pH 6.0. For the matrix regeneration, 0.02 M Mes including 2 M
NaCI at pH 6.0 was used.
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CHAPTER IV
RESUL TS AND DISCUSSION

Three main studies performed were: optimization of PC mini-Mab production
condition; mini-Mab purification using protein A Sepharose; and PC purification from
Cohn Fraction IV -1 using the purified mini-Mab. Experimental results presented in this
dissertation are from at least two sets of experiments, unless specified otherwise.

A. PROCESS OPTIMIZATION OF THE MINI-MAB PRODUCTION

1. Selection ofthe Highest Mini-Mab Producing E. coli Colony

To produce the mini-Mab using E. coli, there are two stages of bioprocesses: a
stage of E. coli growth and then a stage of the mini-Mab production by the E. coli.
The original protocol for the mini-Mab production, which was provided by
Sierks, was with 2XTY media including 1 % of glucose; at 37°C; and at a rate of shaking
300 rpm for the growth of the colony and with 2XTY media including 1 mM of IPTG, 1
mM PMSF, and 0.1 % of glucose; at 30°C; at a rate of shaking 300 rpm; and for 24 hours
of the production time for the mini-Mab production (Wu, et aI., 1998b).
Thirteen E. coli colonies producing mini-Mab against PC, A2FX, A3FX, A4FX,
C1FX, C7FIX, E4FX, E6FIX, E7FIX, E10FIX, G3FX, H3FX, H3FIX, and H12FIX were
tested to select the colony producing the largest quantity of the mini-Mab.
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Figure 4. Mini-Mab production levels by thirteen E. coli colonies.
[Experimental conditions: 30°C, initial pH 7.0, and 0.1 % glucose]

After the completion of the production, the amount of the mini-Mab in the
supernatant was quantified by ELISA (Figure 4). Among 13 colonies, E4FX, E7FIX, and
H3FIX colonies produced much more than others, approximately 10

~

15

~g/ml

of the

mini-Mab in the supernatant. The production by E4FX was the greatest and was selected
for further studies.

2. Glucose Concentration

Since the mini-Mab

IS

produced using lac operon in E. coli cells, high

concentration of glucose in the production medium inhibits the mini-Mab production by
catabolic inhibition (Rousch, et aI., 1998). Therefore, the effect of the glucose
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Figure 5. The effect of glucose concentration on mini-Mab production.
[Experimental conditions: 30°C and initial pH 7.0]

concentration in the production media on the mini-Mab production was examined at
various glucose concentrations, while other media composition remained constant (Figure
5).
When the glucose was not added to the production media, mini-Mab production
was 272 /-Lg/ml. The mini-Mab production level was the highest (320 /-Lg/ml) at a glucose
concentration of 0.1 %. The mini-Mab production appeared to be associated with the cell
growth in the production medium because the final cell density for the medium with 0.1
% glucose was approximately 3 times higher than that for the medium without glucose.

At a concentration of 1 % and when the medium was not changed from the growth
medium to the production medium, there was no mini-Mab production.

At a high

glucose concentration, acetate may have been formed and inhibited the mini-Mab
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production (Imanaka, et aI., 1973). The glucose concentration at 0.1 % was kept for our
further studies, as in the original protocol.

3. Optimal Times for the Cell Growth and for Mini-Mab Harvest
Optimal Time for the Completion of Cell Growth. At the end of the first stage,
when the medium optical density (O.D.) becomes 0.9, cells are separated from the growth
medium and transferred to the mini-Mab production medium.

In order to accurately

predict the time for the completion of the cell growth without frequently measuring the
optical density of the growth medium, the growth of E4FX was observed with respect the
time.
As can be seen in Figure 6, the lag phase lasted for hours. Then during the
exponential growth phase, the doubling time ofE4FX was approximately 30 minutes.
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Figure 6. Cell growth curve of E. coli HB2151 E4FX. [Experimental
conditions: 35°C and 1% glucose]
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The time to reach the O.D. of 0.9 after the cell inoculation was approximately 5 hours
and 30 minutes with very little deviation.
Optimal Production Time. In the original protocol, the time for completing miniMab production after adding the inducer IPTG was 24 hours. To obtain the optimal time
for the mini-Mab harvest, the concentration of the mini-Mab in the medium was
measured in time (Figure 7).

Over the initial five hours, very little mini-Mab was

produced. Then from 5 to 15 hours, the mini-Mab production was almost linear with
time and the production was complete at the time of 18 hours. After 18 hours, the
amount of the mini-Mab decreased, showing possible mini-Mab degradation by protease
in the medium. Therefore, 18 hours after adding IPTG, was selected as our optimal miniMab production time.
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Figure 7. Mini-Mab production time after adding oflPTG. [Experimental
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4. Effect of the Production Medium pH on the Mini-Mab Production
The pH in the growth medium at O.D. 0.9 is approximately 6, the initial pH of the
mini-Mab production medium is 7, and the pH of the production medium after
completing the mini-Mab production is 9. Since there are significant changes in the
media pHs at the end of the cell growth, at the beginning and at the end of the mini-Mab
production, the effect of initial pH on the mini-Mab production was investigated.
The initial pH of the production medium was adjusted at various pHs between 5
and 9 and the mini-Mab production was quantified (Figure 8). The final pH for the one
starting at pH 5.0 was 5.3 and no mini-Mab production was observed.

The final

production media pHs of all other cases were between 8.4 and 8.8. The mini-Mab
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Figure 8. The effect of initial pH of the production media on the mini-Mab
production. [Experimental condition: 18 hours of production time, 30°C, and
0.1 % glucose]

34

production levels at the initial pH 5.5 and 6 were similar and the greatest. For ones at pH
higher than 6, production decreased as pH increases. At the pH 9, the production is only
1/3 of that of the pH 5.5 or 6.0. The pH between 5.5 and 6.0 was decided to be the
optimal initial pH for mini-Mab production.

5. Temperature
It was reported that the production of the mini-Mab produced by phage display

method is affected by temperature (Kempf, et aI., 2001). The effect of temperature on the
mini-Mab production was, therefore, investigated in a temperature range of 23-35 °C
(Figure 9).
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Figure 9. The effect of temperature on mini-Mab production. [Experimental
condition: 18 hours of production time, initial pH 7.0, and 0.1 % glucose]

35

The production at temperature up to 30°C showed a constant level of around 320
)..lg/ml. The production level at 33°C was significantly low, and at 35 °c, the production
was almost zero. The results show that the production is stable at a reasonable room
temperature as long as the temperature is below 30°C.

6. IPTG Concentration
The most expensive component of the production medium is the inducer,
isopropyl P-D-thiogalactopyranoside (IPTG).

The IPTG concentration used in the

original protocol was 1 mM (Wu, et aI., 1998). The study performed by Korah, et al.
(2003b) showed that when IPTG was used at a level of 1 mM, its cost becomes 25 % of
the total media cost. IPTG concentrations of 0, 0.05, 0.1, 1, and 2 mM were tested by
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Figure 10. The effect of IPTG concentration on mini-Mab production.
[Experimental condition: 18 hours of production time, 30°C, and 0.1 %
glucose]

36

Korah, et al. (2003b). It was found that the production rate of mini-Mab was the greatest
at 0.1 and 1 mM of IPTG.
Here, the mini-Mab production between at 0.1 and 1 mM of IPTG was
investigated. The results (Figure 10) showed that the production levels of the mini-Mab
at 0.1, 0.5, and 1 mM IPTG concentrations were almost the same.

Therefore, the

optimum concentration of IPTG was confirmed to be 0.1 mM.

7. Lactose as an Inducer
Kilikian, et al. (2000) reported that lactose may be used as an inducer for
recombinant intracellular protein production.

The amount of the chicken muscle

Troponin C produced by the recombinant E. coli using lactose as an inducer (96 mg/g-dry
cell weight) was similar to that using IPTG (110 mg/g-dry cell weight).
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Figure 11. The effect of lactose as an inducer on mini-Mab production.
[Experimental condition: 18 hours of production time, 30°C, and 0.1 %
glucose]
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Since lactose is approximately 1 % of the cost of IPTG, lactose at three different
concentrations, 15 (40 mM), 25 (70 mM), and 35 giL (97 mM) fallowing the
concentrations used by Kilikian, et al. (2000) were tested (Figure 11). Very little miniMab was produced at all three lactose concentrations and it was concluded that lactose
was not proper as an inducer for the mini-Mab production.

8. Mini-Mab Release from E. coli Cells
The mini-Mab developed by Dr. Michael Sierks at Arizona State University was
designed to release mini-Mab outside of E. coli cells (Wu, et aI., 1998a). However, the
actual mini-Mab release status was not confirmed. Korah (2002) has previously tested
the release of mini-Mabs in the E. coli cells by loosing cell membranes using
ultrasonication and found that ultrasound denatured the mini-Mab, indicating that the
mini-Mab is pressure sensitive.
Sucrose. There have been reports that a high level expression of mini-Mabs in E.
coli often results in aggregation after their transport to the periplasm (Whitlow and

Filpula, 1991; Kipriyanov, et aI., 1994). Kipriyanov, et aI. (1997) also reported that
sucrose at 0.4 M helped the aggregated mini-Mab secrete outside of E. coli because
sucrose is small enough to diffuse into the periplasmic space of E. coli but not
metabolized. Therefore, the sucrose effect on the PC mini-Mab release was tested. The
production medium was prepared with and without sucrose. The mini-Mab production
was performed.

Mini-Mab concentrations in the medium were measured after the

completion of the mini-Mab production (Figure 12). The mini-Mab concentration in the
medium with sucrose was 20 % lower than that without sucrose.
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Figure 12. The effect of sucrose on the mini-Mab release. [Experimental
condition: 18 hours of production time, 30°C, and 0.1 % glucose]

Detergent and Membrane Reactive Cationic Peptides. There have been studies on
the release ofthe recombinant proteins from the periplasm using non-ionic detergents and
cationic peptides, such as, tetraethyleneglycolmonodecyl-ether, Triton X-IOO, and
phospholipase A2 (Morbe, et ai., 1997). The outer membrane of gram-negative bacteria
is impermeable to macromolecules. Only some hydrophobic molecules, such as nonionic detergents, may diffuse through the lipopolysaccharide (LPS), which is a major
component of membranes (Nikaido, 1990).

Cationic substances, such as cationic

peptides, bind to the LPS containing membranes because of the polyanionic nature of the
membrane, leading the membrane permeable (David, et ai., 1996).
Therefore, in this study, two reagents, phospholipase A2 in PBS and Triton X-100
were tested in PBS buffer.
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After 18 hours mini-Mab production, the cells were separated using the centrifuge
at 4,000 rpm for 20 minutes, washed with PBS buffer, and re-suspended in 5 ml of PBS
buffer. The permeabilizing agents were added to the cell-containing buffer at a final
concentration of 0.4 /-lg/ml for phopholipase A2 and 2 % for Triton X-IOO. PBS buffer
was used as a control.
After 40 minutes of reaction, the cells were separated by centrifugation at 4,000
rpm for 20 minutes, and the mini-Mab in the supernatant was quantified by ELISA
(Table 2). In the PBS buffer (control), approximately 50 /-lg of mini-Mab was measured
and in phospholipase A2 showed less mini-Mab release. When triton X-I 00 was used, no
mini-Mab was detected by ELISA.
Therefore, it is concluded that most of the mini-Mab produced by E. coli is
released outside of the cell or the reagents tested are not effective on releasing the miniMab from the cell.

Table 2. The effect of a membrane reactive cationic peptide (phospholipase A2)
and a detergent (Triton X-IOO) on the mini-Mab release from the cell.
[Experimental condition: a final concentration of 0.4 /-lg/ml for phopholipase A2
and 2% for Triton X-IOO]
Total mini-Mab release
detected by ELISA ()lg)
PBS buffer (control)

51.2±2.1

Phospholipase A2

17.5±0.05

Triton-l 00

-
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9. Effects of PM SF on Mini-Mab Production and Storage
In the original protocol of the PC mini-Mab production, 1 mM of PMSF was
added in the production medium (Wu, et aI., 1998). Mini-Mabs have been reported to be
degraded by the proteases in the medium and a serine protease inhibitor PMSF has been
frequently added in the production medium to inhibit the protease activity (Whitlow, et
aI., 1993). It was also reported that PMSF improved the antibody stability during storage
at 4 °c (Brichta, et aI., 2003). PM SF is, however, toxic in human body by inhibiting the
serine protease (Bollen, et aI., 1988).

Here, the effects of PM SF on the mini-Mab

production and on preventing the mini-Mab from being degraded during storage were
investigated.
PMSF was added to the production medium at a concentration of 0, 0.1, or 1 mM
and the production was preceded. At the end of the production, the amount of the miniMab in the supernatant was quantified by ELISA (Table 3). The mini-Mab production
decreased with the increase in PMSF concentration. At the PM SF concentration of I
mM, the production level was only 60 % of the one with no PMSF. When the mini-Mab
production was studied per unit dry cell weight, the mini-Mab production levels for both
with and without PMSF were approximately the same, i.e. 90 mg/g-dry cell weight.

Table 3. The effect of PM SF on the mini-Mab production. [Experimental
condition: 0.1 mM of IPTG concentration, initial pH 6.0, and 18 hours of
production time]
PM SF

Mini-Mab concentration (Ilg/ml)

Mini-Mab production
per cell weight (mg/g)

No PMSF

560±35

90.0±16

0.1 mM

430±88

90.1±18

ImM

350±74

90.0±19
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However, the total cell mass for the medium with 1 mM of PMSF was approximately 40
% less than that without it, showing possible cell growth inhibition by PMSF.
The effect of PMSF on the mini-Mab degradation during the mini-Mab storage
was also studied. The culture broth was divided into six portions: Two were stored in

-70 DC without PMSF, with or without cells for 12 days; two were stored at 4 DC with 3
mM of PMSF, with or without cells for 9 days; the other two were stored at 4 DC without
PMSF, with or without cells for 9 days. After the storage, the mini-Mab in the medium
was quantified by ELISA (Table 4). When the culture broth was stored at -70 DC, the
mini-Mab was kept well with no activity reduction for both with and without cells. At 4
DC, even with PMSF, there was significant degradation (> 22%). In the medium without

PM SF , there was 10 - 16% more degradation than that with PM SF . When cells were
present in the medium, the degradation was approximately 15 % more than without cells.
From the study result, it is concluded that the best way of storing the mini-Mab produced
medium is storing at -70 Dc. If the medium has to be stored at 4 DC for some reason, the
cells should be removed first and stored with PMSF.

Table 4. The effect of PM SF on the mini-Mab storage.
Storage temperature

- 70°C (12 days)

4°C
(9 days)

Storage conditions

Mini-Mab concentration
(ggIml)

Initial Concentration

351±35

wlo PMSF, wi and wlo cells

351±16

wi PMSF, wi cells

211±15

wi PMSF, wlo cells

274±12

wlo PMSF, wi cells

153±28

w/o PMSF, wlo cells

240±45
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B. MINI-MAB PURIFICATION
1. Mini-Mab Purification Using Protein A
Protein A is a cell wall protein of Staphylococcus aureus and has affinity to the
VH domain of a mini-Mab (Akerstrom, et al., 1994; Wilkinson, 2000). Korah (2002)
previously reported 18 % of PC mini-Mab purification yield using the protein A
immobilized CNBr-activate Sepharose™ at a elution buffer pH 3.0.

For the matrix

preparation, she immobilized 0.45 g of protein A for 1 ml of CNBr SepharoseTM. In this
study, the mini-Mab was purified by a commercially available protein A immobilized
CNBr-activated

Sepharose™

CL-4B

matrix

(protein

A

Sepharose™).

The

manufacturer's specification states that approximately 2 mg of protein A can be
immobilized per 1 ml gel of the CNBr-activated Sepharose™ CL-4B. 100 ml of miniMab containing supernatant at a mini-Mab concentration of approximately 450 /-tg/ml
was applied to a column containing 1 ml of protein A Sepharose TM. After the adsorption
and washing steps, the glycine buffer of pH 3.0 (Korah, 2002) was applied to elute the
adsorbed mini-Mab. The amount of mini-Mab in the eluate was quantified by ELISA.
The purification yield [(mini-Mab mass in the eluate)/(mini-Mab mass in the applied
supernatant) x 100] was 35 % (Table 5).

Table 5. Mini-Mab purification by Protein A Sepharose™. [Experiment
conditions: 1 ml of gel matrix and 0.015 cm/s oflinear velocity]
Elution buffer

pH

Yield ofmini-Mab purification (%)

Glycine

3

35±1.4

Citric acid

3

34±1
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For the PC purification, the purified PC mini-Mab needs to be immobilized on the
affinity gel matrices.

The glycine buffer (linear structure formula: NH2-CH2-COOH)

used for the mini -Mab purification has a NH2 residue and the residue was found to
compete with the mini-Mab during the immobilization of the mini-Mab on the matrix.
Therefore, another buffer that does not interfere the immobilization efficiency was
explored. Citric acid [CH2(COOH)-COH(COOH)-CH2(COOH)] buffer was investigated
at the elution pH of 3.0. For the purpose of mini-Mab purification, three different pHs of
the elution were tested. Table 5 shows the purification yields of mini-Mab eluates by
glycine and citric acid buffers. The yield of the mini-Mab eluted by citric acid buffer was
34 %, which is similar to that by glycine buffer. For further studies, citric acid was used
for the mini-Mab elution.

2. Electrophoresis of Mini-Mab Purified from the Production Supernatant.
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Figure 13. Electrophoresis of the samples of the mini-Mab purification from the
production supernatant on Protein A Sepharose™
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Various fractions from the mini-Mab purification process were analyzed by gel
electrophoresis under non-reduced conditions (Figure 13). The result showed a single
band around 30 kDa of the molecular weight, indicating that the eluate contains only the
mini-Mab.

C. PC PURIFICATION
1. Cross reactivity of mini-Mab against PC and PC homologues
Using the purified mini-Mab, the cross reactivity against PC and PC homologues
was investigated by ELISA. The mini-Mab at a concentration of 2

~g/ml

was applied on

each well of ELISA plate and each 1 ~g/ml of PC and PC homologues was adsorbed on
the mini-Mab and 1

~g/ml

of each monoclonal antibody against the PC and PC

homologues were applied to the adsorbed PC and PC homologues.
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Figure 14. Cross reactivity ofmini-Mab against PC and PC homologues.
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The optical density (O.D.) of the developed color in ELISA wells were measured
at a wavelength of 450 nm (Figure 14). The optical densities generated by factors II, VII,
and X were minimal, indicating that the mini-Mab has little cross reactivity against the
factors II, VII, and X. However, factor IX showed 1.5 times higher O.D. of PC.

2. Selection of Gel Matrices
When a biomolecule is covalently immobilized on matrix, the length of the spacer
arm on the matrix may affect the activity of the immobilized biomolecule (Kang, et aI.,
1992). To study the effect of spacer arm length on PC purification performance of gel
matrices, commercially available, four gel matrices with various lengths of the spacer
arm were selected.

They are CNBr Sepharose™, Actigel™, NHS Sepharose™, and

Epoxy-activated™ CNBr Sepharose™ is 4 % agarose and reacts with amine residues of
ligands for immobilization via one oxygen atom spacer (Eq. 1; Amersham Biosciences).

Matrix-OCN(OH) + H,N-mini-Mab

--> matrix-O(O)C~N-mini-Mab

+ NH 40H

(1)

Actigel™ is 4 % cross-linked agarose and its monoaldehyde group reacts with amine
residues of proteins, via 5-atom spacers (Eq. 2; Sterogene Bioseparations).
Matrix-5 atom spacer-CHO + H2N-mini-Mab + reducing agent (NaCNBH3)
-->

Matrix-5 atom spacer-CH2-NH-mini-Mab + H 20

(2)

NHS Sepharose ™ is 4 % cross-linked agarose and has 6-amino-hexanoic acid forming
10-atom spacers of oxygen and carbon. The terminal carboxyl group is activated by
esterification with N-hydroxysuccinimide (NHS) and the amino group of the mini-Mab
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couples to this active ester to form a stable amide linkage (Eq. 3; van Sommeren, et aI.,
1993).
Matrix-O-C(O)-CH2-NH-(CH2),-COOH + H2N-mini-Mab
-->

Matrix-O-C(O)-CH,-NH-(CH2),-CO-NH-mini-Mab + H 20

(3)

Epoxy Activated matrix is 4 % cross-linked agarose and its epoxy group binds to amines
of the ligands via 12-atom spacer of oxygen and carbon (Eq. 4).
Matrix-O-CH2-CH(OH)-CH,-O-(CH2).-CH2-CH(O)-CH2 + H2N-mini-Mab
-->

Matrix-O-CH,-CH(OH)-CH,-O-(CH2)4-CH,-CH(OH)-CH,-NH-mini-Mab

(4)

Korah et aI. (2003a) has tested CNBr Sepharose™ and Actigel™ for PC
purification using pure PC. Actigel™ showed a PC purification efficiency higher (10%)
than CNBr Sepharose™ (6 %), indicating that the matrix with a longer spacer arms may
keep the 3-D structure of the immobilized mini-Mab better.
2 mg of the mini-Mab was reacted with 1 ml of each matrix. The mini-Mab
immobilization efficiencies of the CNBr Sepharose™, Actigel™, NHS Sepharose™, and
Epoxy Activated™ matrices were approximately 85, 85, 95, and 70 %, respectively,
showing NHS Sepharose with the highest (Table 6).

Each matrix was packed in a

column, the PC performance was tested using 20 fig of pure PC, and the PC in the eluate
was quantified by ELISA (Table 6).

The purification efficiency was presented as a

normalized PC amount per 1 mg of the immobilized mini-Mab on the matrices. CNBr
Sepharose ™ showed the worst purification efficiency probably because the mini-Mab
bound to the matrix via a very short spacer, losing its original three dimensional
conformations (Kang, et aI., 1992). Actigel™ showed a reasonable performance and
NHS Sepharose ™ has shown the best performance for the PC purification (54 %).
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Table 6. PC purification performance by mini-Mab immobilized matrices.

CNBr
Sepharose™*l

Actigel™

NHS
Sepharase™

Epoxy
Activated™

1

5

10

12

0.85

0.S5±0.03

0.95±0.02

0.7

PC purification yield" (e2)

0.06±0.01

O.4S±O.IS

0.54±0.11

OJO±0.07

Normalized PC purification
yield ().lg-PC/mg-mini-Mab)

1.l±OJ

5.6±2.1

5.7±1.8

4.9±1.0

Matrix productivity
(el x e2)

0.05

0.41

0.51

0.21

Length of the spacer
(number of atoms)
Mini-Mab
immobilization

efficiency"(el)

'I: The study uSing CNBr Sepharase was performed by Korah (2002).
'2 (el) and '3 (e2): The related information was reported by Kang, et al. (1992).

The normalized PC purification yield of NHS Sepharose ™ showed that I O-atom
spacer arms have kept the activity of the immobilized mini-Mab well.

Epoxy

Activated™ has spacers longer than NHS Sepharose™ but showed lower immobilization
efficiency than other matrices and also the immobilized mini-Mab on the gel showed a
purification performance inferior to that of Actigel™ or NHS Sepharose TM. Kang, et al.
(1992) evaluated the matrix performance by the coupling efficiency of ligand (El), the
product adsorption efficiency of ligand (£2), and the specific activity of the eluted product

(E3). Here, the mini-Mab immobilization efficiency (El) and PC purification yield (E2) of
the matrices were used to study the PC purification performance, assuming that the
activities of the purified PC by the matrices are the same. The NHS Sepharose™ showed
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the best PC purification performance and, therefore, NHS Sepharose™ was selected for
the further PC purification studies.

3. PC Purification from the PC Homologues Mixture
As previously stated, PC sources, plasma and Cohn Fraction IV -I include many
proteins homologues to PC and these homologous proteins are coagulants. To study the
optimal amounts of the mini-Mab immobilized on NHS Sepharose™ for PC purification,
2, 4, and 6 mg of the purified mini-Mab were immobilized on I ml of the NHS
Sepharose™ matrix each. A mixture of PC and PC homologous coagulant factors was
used as a source material and PC purification performance of each matrix was studied.
Commercially available PC homologous blood clotting factors were mixed with
PC following the physiological ratio in plasma, i.e., PC, 4; factor II, 90; factor VII, 0.5;
factor IX, 4; and factor X, 6.4 J.lg/ml. The actual amounts of proteins were: PC, 20;
factor II, 450; factor VII, 2.5; factor IX, 20; and factor X, 32 J.lg, in the final volume of
500 J.ll. PC and PC-homologues in the fraction at various chromatography steps were
quantified by ELISA (Table 7).
When 2 mg of the mini-Mab was used, approximately 85 % of PC was washed
away, showing much less adsorption compared with the case with PC only.
Nevertheless, more than 95 % of PC homologues were also washed away. During the
elution process, 14 % of PC yield was recovered, much less than when the pure PC was
used as the source material (54%).

For the PC homologues, less than 5 % of PC

homologues remained in the eluate. However, the amount of factor II in the eluate was
greater than that of PC, because of its large amount in the source material (more than 20
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times greater than PC). Factor IX, which showed a high affinity to the mini-Mab for the
ELISA did not remain in the column.
For the matrix with 4 mg of the mini-Mab, 73 % of PC was washed away, 10 %
less than that with 2 mg. As in the matrix with 2 mg ofmini-Mab, more than 95 % of PC
homologues were washed away. The amount of factor II in the eluate was less than that
of PC. During elution, yield of26 % was obtained.

Table 7. PC purification efficiency when 2 mg, 4 mg, or 6 mg of the mini-Mab
was immobilized in 1 ml of the matrix. The source material was the mixture of PC
and four PC homologues. [Experiment conditions: 0.015 cm/s of linear velocity,
and 10 minutes of reaction time1
Amount of
immobilized
mini-Mab
(mglmlmatrix)

Purification
steps

Amount of factors

PC

FIl

FVII

FIX

FX

17.1±1
(85±3)

44l±1
(98±0.3)

2.5±0.1
(99±!)

19.6±0.1
(98±0.!)

30.2±0.6
(95±2)

14.6±1
(73±9)

44l±5
(98±!)

2.4±0.1
(97±2)

!9.7±0.2
(98±!)

30.7±0.!
(96±0.!)

14.6±1
(73±3)

442±5
(98±!)

2.4±0.!
(95±3)

!9.6±0.3
(98±1)

31.2±0.9
(97±3)

2.7±!
(l4±3)

5±1
(1±0.2)

0
(0)

0.l±0.1
(0.3±0.2)

1.l±1.2
(3±4)

5.2±!
(26±4)

5±5
(1±1)

0.1±0.!
(2±3)

0.1±0.1
(0.7±0.7)

0.5±0.4
(2±1)

5.2±1
(26±3)

7±4
(2±1)

0.1±0.!
(4±5)

0.2±0.2
(1.l±1.0)

0.7±0.8
(2±2)

--

Ilg

2

Washing

(%)
Ilg

4

(%)
Ilg

6

(%)
Ilg

2

Elution

(%)
Ilg

4

I

I

(%)
Ilg

6

(%)

I

.

-~--.
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For the NHS matrix with 6 mg of the mini-Mab, 73 % of PC was washed away,
which is similar to that with 4 mg of mini-Mab, and more than 95 % of PC homologues
were washed away. The PC purification yield of 26 %, similar to that of the matrix
immobilized with 4 mg ofmini-Mab, was obtained. The amount of factor II in the eluate
was greater than that of PC. The amounts of other PC homologues in the eluate (factors
II, IX, and X) were slightly more than those in the case of the 4 mg mini-Mab.
This study result shows that the NHS Sepharose matrix with 4 mg mini-Mab
showed the best performance and was used for further studies for PC purification from
Cohn Fraction IV-\'

The result also shows that PC purification yield decreases

significantly when there are other PC homologous proteins exist in the source material
and the amount of factor II in the eluate is similar to or slightly more than that of PC.

4. Purification of PC from Cohn Fraction IV-I
Quantification of PC and PC Homologues. It has been reported that I kg of Cohn
Fraction IV -I paste had approximately 100 mg of PC (Wu, et aI., 1998).

The

concentrations of the PC homologues in Cohn Fraction IV -I, however, have not been
quantified. Here, PC and the PC homologues in the Cohn Fraction IV -I were quantified
using ELISA.
Following Wu's protocol (2000b), approximately 22 g of Cohn Fraction IV-I
paste was dissolved in 440 ml of sodium citrate buffer (approximately 20 times dilution
ratio; pH 6.0) and placed for 5 hours, at 4 DC, with stirring at 100 rpm.

After the

centrifugation of the paste solution at 4000 rpm for 20 minutes, PC and the homologues
in the supernatant were quantified using ELISA (Table 8).
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Table 8. Amounts of PC and PC homologues in Cohn Fraction IV-I paste.
------ ,-- ----"..• -------- . ----------- - , . ,•.. ___ 0'_. - - - - _ . -

PC
.

Human plasma
(Ilgiml)

Fraction IV-1
(mglkg-paste)

After the filtration of
Cohn Fraction IV-1
(mg/kg-paste)
In

FVII

FIX

FX

HSA

90
[23]

0.5
[0.13]

4

[1]'

[1]

6.4
[1.6]

40000
[ 10000]

103.9±3.4
[1]

1201±178
[12]

29.3±5.7
[0.3]

13.5±3.1
[0.13]

269±18
[2.6]

24812±5720
[239]

95.5±2.3

1171±15
[12]

20±1.2
[0.2]

9.2±0.2
[0. I]

264±9
[2.8]

22777±4410
[239]

4

Supernatant of Cohn

[ ]*: the numbers

FII

__.._ -

[II

brackets are showmg the ratio of the amount of factors to PC amount.

The amount of PC in the supernatant was determined to be approximately 100
mglkg-paste and the ratio of the amount of factors VII and IX to that of PC's was much
less. The amounts of factor X was approximately 3 times more than that of PC. The
amounts of factor II was shown to be approximately 1200 mg/kg-paste.

For human

serum albumin (HSA), which is the most abundant protein in plasma, the amount ratio to
that of PC was forty times less than that in plasma.
The supernatant was then filtered using polyethersulfone filters (0.8, 0.45, and 0.2
flm of pore sizes, respectively) to remove particulate before applying it to mini-Mab
immobilized gel matrix [or the PC purification. After filtration, approximately, 8 % less
amount (96 mg/kg-paste) of PC and 2-32 % less homologues were found in the filtrate
(factor II; 1171, factor VII; 20, factor IX; 9.2, and factor X; 264 mglkg-paste).
Effect of Adsorption pH on PC Purification Performance. The usual pH used for
either plasma or in Cohn Fraction IV -1 is 6.0, to reduce the activity of protease present in
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plasma (Amaral, et aI., 2003; Vazquez-Lopez, et aI., 1999). ELISA was carried out to
study the affinity of the mini-Mab to PC at pH 6 and 7. The mini-Mab at pH 7 showed
the affinity to PC 30 - 40 % higher than that in pH 6 (data not shown). Next, the effect
of pH on the performance of the mini-Mab immobilized, PC affinity chromatography was
studied. The pH of the source material was also adjusted to either pH 6 or 7. 4 ml of the
Cohn Fraction IV -1 filtrate (total PC amount, 15 /-lg) was applied to the mini-Mab
immobilized NHS matrix and the PC purification was performed. The amount of PC at
various purification stages were determined by ELISA (Table 9).

Table 9. Amount of PC and PC homologues in various fractions during
purification process from Cohn Fraction IV-l at pHs of 6.0 and 7.0. The amount
of the factors in washing and elution. [Experiment conditions: 1 ml of gel matrix,
0.015 cm/s oflinearvelocity, and 10 minutes of reaction time]

Amount of factors
Purification
steps

pH

6

/!g

(%)

PC

FII

FVII

FIX

FX

1l±2
(73±8)

464±209
(93±7)

1.2±0.5
(98±1)

1.3±0.4
(86±9)

2.7±O.l
(96±5)

1l±2
(73±17)

475±180
(96±1)

1.2±0.5
(99±1)

1.3±0.5
(86±14)

4±2.2
(94±2)

2.4±0.3
(l6±1)

1.2±0.1
(O.3±O.l)

0
(0)

0.003±0.001
(O.3±O.l)

0.0l± 0.003
(O.4±O.l )

1.7±O.l
(ll±l)

0.9±0.1
(0.2±O.l )

0
(0)

0
(0)

0.003±0.003
(0.l±0.1)

Washing
7

6

/!g

(%)

/!g

(%)

Elution
7

/!g

(%)
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In the washing step, 73 % of PC was washed away for both pHs with the similar
percentage of washing for PC homologues. For factor 11,93 and 96 % were washed away
for pH 6 and 7, respectively. Approximately 98 and 95 % of factors VII and X were
washed away for both pHs, respectively. For factor IX, approximately 86 %, less than
the other factors, was washed away.
In the eluate, the amount of factor II was found to be half of the actual PC
amount. For the other factors, less than 0.4 % was found in the eluate for both pHs. The
PC in the eluate quantified by ELISA was shown to be 16 and 11 % at pHs of 6 and 7
respectively, showing approximately 5 % higher yield with pH 6, and possible PC
degradation at pH 7.0. The yield of 16 % at pH 6.0 from the Cohn Fraction IV-l is also
almost a half of the yield from PC homologues mixture (26 %).
Effect of HSA in the source material on PC Purification Performance.

As

previously shown, there is a reduction in the purification yield for the sample of the
mixture of PC and PC homologues compared with the sample with PC only. In the
presence of large quantity of other molecules, PC molecules do not get to be transported
to the mini-Mab well. Although human serum albumin (HSA) in Cohn Fraction IV -1 is
only 1/30 of that in plasma, the amount is still 240 times greater than that of PC.
Therefore, it was speculated that this large amount of HSA may hinder the diffusion of
PC molecules.

Therefore, the effect of the presence of large amount of HSA in the

source material on PC purification was systematically studied. Sample composed of PC
and PC homologues at a physiological concentration ratio in plasma (PC, 20; factor II,
450; factor VII, 2.5; factor IX, 20; and factor X, 32 Ilg) with or without HSA (0.2 g) was
applied to the mini-Mab immunoaffinity chromatography column and the purification
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process was performed. Each factor in washing and elution steps was quantified by
ELISA (Table 10).
In the washing step, for the sample without HSA, approximately 75 % of PC was
washed away and for the samples with HSA, 88 %. For factor VII, 87 and 82 % were
removed for the samples without and with HSA, respectively. For other factors, more
than 96 % was removed.
In the elution, the PC purification yields were shown to be 12 and 25 % for the
samples with and without HSA, respectively, showing that, with HSA in the source, the
yield is reduced by approximately 13 %. The results show that the large quantity of HSA
in the source material interferes the PC purification yield.

Table 10. Effect of HSA on PC purification. The amount of the factors in
washing and elution steps (a) without and (b) with HSA. [Experiment conditions:
1 ml of gel matrix, 0.015 cm/s of linear velocity, and 10 minutes of reaction time]
Amount of factors
Purification
steps
PC

FII

FVII

FIX

FX

HSA

(a)

Ilg
(%)

15±1.4
(75±7)

445±0.6
(99±0.1)

1.7±1.l
(87±I3)

19.5±0.2
(97±2)

31±0.1
(98±0.2)

0
(0)

(b)

Ilg
(%)

18±0.4
(88±2)

448±0.5
(99.6± 0.1)

2.1±O.l
(82±4)

19.5±0.4
(97±2)

31±0.4
(96±4)

198934±1323
(99.5±0.6)

(a)

Ilg
(%)

4.9±1.3
(25±7)

2.1±0.6
(0.5±0.1)

0.2±0.3
(9±1)

0.2±0.1
(1.3±0.4)

0.3±0.1
(0.9±0.3)

0
(0)

(b)

Ilg
(%)

2±0.3
(12±2)

0.6±0.1
(0.1±0.01)

0.5±0.1
(l7±4)

0.02±0.01
(0.2±0.1)

0.2±0.2
(0.6±0.5)

40.9±23
(0.02±0.0 I)

Washing

Elution,
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Effect of Salt on PC Purification.

Since large amount of HSA in the source

material affects PC purification yield significantly, it was also speculated that HSA
molecules get adsorbed to the gel matrix non-specifically and prevent PC molecules from
reacting with their mini-Mabs.

The concentration of NaCI in washing buffer in the

original protocol was 0.08 M and the washing buffer with 0.5 M of NaCI was tested.
Cohn Fraction IV -1 with the PC amount ranging 15 - 20 Ilg was applied to the column
and the PC purification was performed using the washing buffer at 0.5 M NaCl. The PC
and PC homologues in washing and elution steps were quantified using ELISA (Table
11 ).

Table 11. Effect of the salt concentration in washing buffer on the purification of
PC from Cohn Fraction IV-I. The amount of the factors in washing and elution
steps when the washing buffer contains (a) with 0.08 and (b) 0.5 M NaCl.
[Experiment conditions: 1 ml of gel matrix, 0.015 cm/s of linear velocity, and 10
minutes of reaction time]

Amount of factors
Purification
steps

(a)

Ilg

(%)

PC

FII

FVII

FIX

FX

HSA

11±0.4
(77±3)

533±90
(98±0.5)

4±4
( 97±2)

1.2±0.5
(98±0.1)

6.2±2.7
(98± 1)

5737±19
(99±1)

18±2.3
(97±3)

618±21
(97±4)

3±1
(89±8)

1.0±0.4
(99.5±0.7)

7.5±0.6
(99±1)

6725±35
(99.8±0.1)

2±0.1
(l5±0.4)

l.3±0.1
(0.2±0.1)

0
(0)

0
(0)

0.1±0.01
(1.6±0.1)

4±3.1
(0.1± 0.01)

0.1±0.1
(0.3±0.1)

0.7±0.2
(0.1±0.01)

0.5±0.5
(1l±2)

0
(0)

0.02±0.01
(0.3±0.1)

15±0.3
(0.1± 0.01)

Washing

(b)

(a)

Ilg

(%)

Ilg

(%)

Elution
(b)

Ilg

(%)
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During the washing step, for the washing buffer with 0.08 M NaCl, 77 % of PC
was washed away, while 97 % of PC was removed for the buffer with 0.5 M NaCl. For
other factors, more than 97 % were removed during the washing step both cases, but
factor VII showed less amount of washing for using the buffer with 0.5 M of NaCl. In
the elution, the PC purification yields were IS and OJ % when the washing buffer had
0.08 M and 0.5 M of NaCl, respectively, showing that high salt concentration affects the
PC adsorption to the mini-Mab. For other factors, less than 2 % remained for both cases
except the factor VII remained more with 0.5 M NaCl.

5. Electrophoresis of Eluate of the PC Chromatography using Cohn Fraction IV-l
Electrophoresis was performed for commercially available PC, PC homologous
factors, human serum albumin, and the fractions from the PC purification process from
the Cohn Fraction IV -I under non-reduced condition (Figure IS).

2

3

4

5

6

7

8

Lane
1; PC

2; factor 11
3; facto r VII
4; factor IX

5; factor X
6; HSA

7; Cohn Fraction IV-l
8; PC eluate.

Figure IS. Electrophoresis ofthe samples from PC purification from Cohn
Fraction IV -I using the mini-Mab immobilized NHS Sepharose™
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The result showed that the mini-Mab PC affinity chromatography removed the
proteins with molecular weights lower than PC. There are a single band around the
molecular weight of PC (PC, factor II and human serum albumin, based on ELISA
result). Two bands at the molecular weights greater than PC were also found in the
eluate.

6. Removal ofHSA by DEAE Ion Exchange Chromatography
The isoelectric point (PI) of PC is

4.4~4.8

and the pI of HSA is 5.7 (Bordbar, et

aI.,2004). From the fact that a low PC purification yield occurs with the source material
with high HSA concentration and there is a difference in pI between PC and HSA, ion
exchange chromatography was considered to remove HSA before the mini-Mab affinity
chromatography step.
Approximately 1 ml of the DEAE Sepharose™ Fast Flow matrix was packed in a
col umn of the diameter at 0.7 cm. Then 100 ml of a filtered Cohn Fraction IV -1 solution
was applied to the column and ion exchange chromatography was performed using a pH
of 6.0 for adsorption/washing. PC, PC homologues, and HSA in washing and elution
steps were quantified by ELISA (Table 12).
The yield of PC was approximately 65 % and 10

~

20 % of factors II, FIX, and

FX were removed. 95 % of factor VII was removed. For the HSA, more than 99 % was
washed away. The concentration of PC and PC homologues in the eluate became 10
times higher than that in the source, except the factor VII.
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Table 12. The amount of PC, PC homologues, and HSA in the DEAE eluate of
Cohn Fraction IV-I. [Experiment conditions: 1 ml of gel matrix, 0.004 cm/s of
linear velocity, and 4°C]

PC

FII

FVII

FIX

FX

HSA

/lg

644

10428

57

43

462

58857

/lg

214
(33.3)

787
(7.5)

53
(94.4)

5.5
(13)

31
(6.7)

58723
(99.8)

(%)

420
(65.3)

8712
(83.6)

3
(5.3)

36.2
(85)

420.4
(90.9)

40.1
(0.07)

Cone. in the source

/lg/ml

6.4

10.42

0.57

0.42

4.6

590

Cone. in the eluate

/lg/ml

39

800

0.29

3

39

4

Amounts in the
source
Washing,

Elution

(%)

/lg

In summary, DEAE anion exchange chromatography removed most of the HSA
and, PC and factors II, IX, and X were concentrated.

7. PC Purification from the Eluate ofDEAE Chromatography Using the NHS Matrix
The affinity purification of PC from the eluate ofDEAE chromatography of Cohn
Fraction IV -1 was performed using the mini-Mab immobilized NHS matrix. The amount
of PC of the DEAE eluate was approximately 20
eluate was approximately 4

~g.

~g

and the amounts of HSA in the

PC, PC homologues, and HSA in elution step were

quantified using ELISA (Table 13).
Approximately 25 % of PC purification yield was obtained, 9 % higher than that
without the ion-exchange process (16 %). This result confirms that the large amount of
HSA in the source material affects the adsorption of PC to the mini-Mab on the matrix.
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Table 13. PC purification from the DEAE eluate of Cohn Fraction IV-l using
mini-Mab immobilized NHS matrix. [Experiment conditions: 1 ml of gel matrix,
0.015 cm/s oflinearvelocity, and 10 minutes of reaction time]

PC

FII

FVII

FIX

FX

HSA

Amount in the
source

!!g

20

173±7

0.2±0.1

l.5±0.1

24±4

4±1.4

Amount in the
eluate

!!g
(%)

4.9±O.l
(25±0.3)

2.5±1.4
(l.5±0.9)

0.l±0.1
(18±25)

0
(0)

0.l±0.02
(0.2±0.1)

0.3±0.01
(l0±4)

The overall PC purification yield from Cohn Fraction IV -1 is combined value of
the yield from DEAE anion exchange chromatography from Cohn Fraction IV-l (65 %)
and the yield (25 %) by mini-Mab immobilized NHS matrix using the eluate.

It is

approximately 16 %, and is similar to the PC purification yield from Cohn Fraction IV-l
without the ion-exchange process. For the other factors, the overall yields from Cohn
Fraction IV -1 were similar to the values of the combined yields from both DEAE anion
exchange chromatography from Cohn Fraction IV -1 and the purification from the eluate.

8. Electrophoresis of Eluate of the PC Affinity Chromatography Using DEAE Eluate
Electrophoresis was performed for the eluate of the mini-Mab immunoaffinity
using the eluate of DEAE chromatography, under a non-reduced condition (Figure 16).
The PC eluate showed that there is a band around 60,000 Da, possibly for PC, factor II,
and HSA. Two bands are shown at molecular weights greater than PC.
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Figure 16. Electrophoresis of the eluate of PC purification using the miniMab immobilized NHS Sepharose™ with the source of the DEAE eluate.

D. ECONOMIC ANALYSIS OF PC PURIFICATION BY MINI-MAB
A preliminary economic analysis of PC purification using the mini-Mab was
performed by Korah, et al. (2003).

The specific production rate of mini-Mab was

evaluated to be 500 times faster than that of Mab's. With pure mini-Mab, not the
supernatant from the reactor broth, the yield of Mab purification (70 %) was evaluated
1.75 times greater than mini-Mab's (40 %) based on mini-Mab purification using IMAC.
For PC purification study, Korah used pure PC instead of Cohn Fraction IV-I.

PC

purification yield using Mab (70 %) was 7 times better than that using mini-Mab's (10
%).

For the overall economic analysis, Korah (2003) estimated that PC purification
using the mini-Mab is 40 times cheaper than that using regular Mab.
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Table 14. An economic analysis of the production for the mini-Mab using E. coli
and for the Mab using animal cell culture. (modified from Korah's analysis, 2003)

Mini-Mab

Mab

Total cost of Media ($IL)

6.09

Total cost of Media ($/L)

60.18

2XTY

3.45

DMEM·

27.5

IPTG

1.82

Calf serum

30.0

Ampicillin

0.59

Antibiotic

2.68

Glucose

0.23

Production time (day)

1

Production time (day)

4

Production level (g/L)

0.45

Production level (g/L)

0.1

Molecular weight (kDa)

30

Molecular weight (kDa)

150

Overall production rate
(mole/day/dollar)

2.5 x10- 6

Overall production rate
(mole/day/dollar)

2_8xlO-9

Dulbecco's modification of Eagle's Media

Since Korah's preliminary study, there has been more optimization in the miniMab production and the new production rate of the mini-Mab was estimated to be 1000
times better than that of Mab's (Table 14). The mini-Mab purification yield from the
source of the reactor broth was improved and became 34 % by commercially available
protein A affinity chromatography. The yield of PC purification from Cohn Fraction IV-

1 is 16 %.
With these new improvements, PC purification using mini-Mab was re-estimated
as approximately 100 times cheaper than that using regular Mab (Table 15).

62

Table 15. Economic analysis of PC purification using mini-Mab and regular Mab.
Mini-Mab

Mab

Production cost

1

1000

Antibody purification

2

1

PC purification

4.5

1

Overall ratio

9

1000
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CHAPTER V
CONCLUSIONS

The following Conclusions were made for PC production process from Cohn
Fraction IV-1 using mini-Mab produced by recombinant E. coli in this study.
Mini-Mab production. Out of the thirteen HB2151 E. coli colonies, E4FX was
confirmed to be the colony producing the mini-Mab the most and was selected for the
optimization of the mini-Mab production.
The optimum conditions for the mini-Mab production were determined to be 0.1
% glucose; 0.1 mM IPTG; initial pH 5.5

temperature at 23

~

~

6.0; the harvest time of the 18 hrs; and media

30 T. The mini-Mab production level was increased from 15 mg/L

to 450 mg/L after the optimization of the culture conditions. PMSF in the production
media negatively affects the mini-Mab production. The best way of storing the mini-Mab
produced media is at -70°C. If the media has to be stored at 4 °c for some reason, the
cells should be removed first and stored with PM SF .
Mini-Mab Purification. Using commercially available protein A Sepharose, the
mini-Mab was purified from the supernatant of the production media at a yield of34 %.
PC purification. PC purification performance was tested for the mini-Mab using
four commercially available gel matrices. For pure PC, NHS Sepharose™ showed the
best PC purification efficiency of 54 %.
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The optimum amount of the mini-Mab for PC purification was determined to be 4
mg ofmini-Mab per 1 ml ofNHS Sepharose™ gel matrix.
Cohn Fraction IV -1 is an inexpensive source for PC. The amounts of PC in the
fraction were determined to be 104 mg-PClkg-paste. When Cohn Fraction IV -1 is used,
PC purification yield using the mini-Mab immobilized NHS Sepharose™ was 16 %,
much lower the case with pure PC.

When samples of the PC and PC homologues

mixture with and without HSA were tested, the yield of 25 % was obtained without HSA,
while 13 % was obtained with HSA. DEAE anion exchange chromatography was able to
remove 99.8 % HSA from Cohn Fraction IV-1 and 65 % of PC was retained in the eluate.
Also PC was concentrated approximately 10 times during the process. PC purification by
the mini-Mab immobilized NHS Sepharose™ showed 25 % of the PC purification yield
from the eluate ofDEAE chromatography of Cohn Fraction IV-I.
A brief economic analysis showed that the PC purification cost using the miniMab might be approximately 100 times cheaper than that by regular Mabs.
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CHAPTER VI
FUTURE WORK

The following studies are suggested for future studies, to improve PC purification
using mini-Mab.
Mini-Mab production.

It is suggested to produce mini-Mab in a single step

instead of the two stages of growth and production. Scale-up of mini-Mab production
may be beneficial, especially using bioreactors.
Mini-Mab purification. Mini-Mab purification using IMAC may also be studied
as an inexpensive process.
PC purification. Recycling of the PC source material back to the column during
the adsorption step may minimize the loss of PC in the source material. Mechanism of
HSA interfering PC purification may be investigated.

Developing mini-Mab

immobilization methods with less affinity reduction may increase the purification yield
significantly.

66

REFERENCES
l. Akerstrom, B., Nilson, B.H.K., Hoogenboom, H.R., and Bjorck, L. (1994). On the
interaction between single chain Fv antibodies and bacterial immunoglobulin-binding
proteins. J. Immunol. Methods. 177, 151-163.
2. Allaart, C.F. and Briet, E. (1994). Familial venous thrombophilia. In: Haemostasis
and Thrombosis. Bloom, A.L., Frobes, C.D., Thomas, D.P., and Tuddenham, E.G.D.
(Eds.), l349-1360, Churchill-Livingstone, London.
3. Allaart, C.F., Rosendaal, F.R., Noteboom, W.M.P., Vandenbroucke, J.P., and Briet, E.
(1995). Survival in families with hereditary protein C deficiency, 1820 to 1993. BMJ
311,910-912.
4. Amaral, M.M., Kempfer, A.C., Farias, C.E., Carballo, G.A., Silaf, M.R., and Lazzari,
M.A. (2003). Von Willebrand factor cleaving protease activity in the physiopathology
of microangiopathic disorders. Medicina 63, 130-136.
5. Amersham Biosciences Home Page. http://www.amershambiosciences.com
6. Angus, D.C., Birmingham, M.C., Balk R.A., Scannon, PJ., Collins, D, Kruse, lA.,
Graham, D.R., Dedhia, H.V., Homann, S., and MacIntyre, N. (2000). E5 murine
monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled
trial. JAMA 283, 1723-30.
7. Annane, D., Sebille, V., Troche, G., Raphael, lC., Gajdos, P., and Bellissant, E.
(2000). A 3-level prognostic classification in septic shock based on cortisol levels and
cortisol response to corticotropin. JAMA 283, 1038-45.
8. Bajaj, S.P., Rapaport, S.I., and Brown, S.F. (1981). Isolation and characterization of
human factor VII. J. Bio!. Chem. 256,253-259.
9. Baxter (2001). http://baxter.com
10. Bernard, G.R., Vincent, J.-L., Laterre, P.-F., LaRosa, S.P., Dhainaut, J.-F., LopezRodrigueze, A., Steingrub, J.S., Garber, G.E., Helterbrand, lD., Ely, E.W., and
Fisher, CJ. (2001). The Recombinant Human Activated Protein C Worldwide,
(2001). Efficacy and Safety of Recombinant Human Activated Protein C for Severe
Sepsis. N. Eng!. J. Med. 344, 699-709.

67

11. Bollen, M and Stalmans, W. (1988). Fluorine compounds inhibit the conversion of
active type-l protein phosphatases into the ATPMg-dependent form. Biochem. J.255,
327-333.
12. Bone, R.C., Grodzin, CJ., and Balk, R.A. (1997) Sepsis: a new hypothesis for
pathogenesis of the disease process. Chest 112, 235-43.
13. Bordbar, A.-K., Sohrabi, N, and Gharibi, H. (2004) Binding set analysis for
interaction of human serum albumin with cethyl trimethylammonium bromide. Bull.
Korean Chem. Soc. 25,791-795.
14. Bowden, G.A. and Georgiou, G. (1990). Folding and aggregation of ~-lactamase in
the periplasmic space of Escherichia coli. J Bio!. Chem. 265, 16760.
15. Boyer, C., Rothschild, C., Wolf, M., Amiral, J., Meyer, D., and Larrieu, M.J. (1984).
A new method for the estimation of protein C by ELISA. Thrombosis Research 36,
579-589.
16. Brichta, J., Vesela, H., and Franek, M. (2003). Production of scFv recombinant
fragments against 2,4-dichlorophenoxyacetic acid hapten using naIve phage library.
Vet. Med. Czech. 9,237-247.
17. Broze, GJ. Jr. (1994). The tissue factor pathway of coagulation: factor VII, tissue
factor, and tissue factor pathway inhibitor. In: Haemostasis and Thrombosis. A.L.
Bloom, C.D. Frobes, D.P. Thomas, and E.G.D Tuddenham (Eds.), 349-377,
Churchill-Livingstone, London.
18. Bruley, D.F. and Drohan, W.N. (1990). Protein C and related anticoagulants. Gulf
Publishing, Houston.
19. Broze, GJ. Jr. and Miletich, J.P. (1984). Human protein Z. J Cin. Invest. 73, 933938.
20. Carter, P., Bedouelle, H., and Winter, G. (1985). Improved oligonucleotide sitedirected mutagenesis using M13 vectors. Nucleic Acids Res. 13,4431-4443.
21. Cohen, G.N. and Monod, J. (1957). Bacterial permeases. Bacteriol. Rev. 2, 169-194.
22. Cohn, EJ. (1948). The history of plasma fractionation. In: Advances in military
medicine made by American investigators working under the sponsorship of the
committee on medical research. Andrus, ED. (Ed.), 1, 364-443, Little, Brown and
Company, Boston.

68

23. Cohn, E.J., Strong, L.E., Hughes, W.L.Jr., Mulford, DJ., Ashworth, IN., Melin, M.,
and Taylor, H.L. (1946). Preparation and properties of serum and plasma proteins. IV.
A system for the separation into fractions of the protein and lipoprotein components
of biological tissues and fluids. JAm. Chem. Soc. 68,459-475.
24. Colman, R.W., Hirsh, J., Marder, VJ., and Salzman, E.W. (1993). Hemostasis and
Thrombosis. (3 rd ed). lB. Lippincott Company.
25. Comp, P.C. and Esmon, C.T. (1980). Evidence for multiple roles for activated protein
C in fibrinolysis. In: Regulation o/Coagulation. Mann, K.G. and Taylor, F.B. (Eds.),
583-588, Elsevier, New York.
26. Creager, A.N.H. (1999). 'What Blood Told Dr Cohn': World War II, plasma
fractionation, and the growth of human blood research. Stud. Hist. Phil. BioI. &
Biomed. Sci. 30,377-405.
27. Dahlback, B. (1995). The protein C anticoagulant system: inherited defects as basis
for venous thrombosis. Thrombosis Research 77, 1-43.
28. Dahlback, B. and Stenflo J. (1994). A natural anticoagulant pathway: protein C, S,
C4b-binding protein and thrombomodulin. In: Haemostasis and Thrombosis. A.L.
Bloom, C.D. Frobes, D.P. Thomas, and E.G.D Tuddenham (Eds.), 671-698,
Churchill-Livingstone, London.
29. Dalton, lC., Bruley, D.F., and Kang, K.A. (1997). Separation of recombinant human
protein C from transgenic animal milk using immobilized metal affinity
chromatography. Oxygen Transport to Tissue XVIII Advances in Experimental
Medicine and Biology 411,419-428.
30. David, S.A., Awasthi, S.K., Wiese, A., Ulmer, AJ., Linder, B., Brandenburg, K.,
Seydel, u., Rietschel, E.T., Sonesson, A., and Balaram, P. (1996). Characterization of
the interactions of a polycationic, amphiphilic, terminally branched oligopeptide with
lipid A and lipopolysaccaride from the deep rough mutant of Salmonella minnesota.
Journal 0/ Endotoxin Research 3, 369-379.
31. de Fouw, NJ., de Jong, Y.F., Haverkate, F., and Bertina, R.M. (1988). Activated
protein C increases fibrin clot lysis by neutralization of plasminogen activator
inhibitor - no evidence for a cofactor role of protein S. Thromb. Haemost. 60, 328333.
32. Desplancq, D., King, DJ., Lawson, A.D.G., and Mountain, A. (1994).
Multimerization behaviour of single chain Fv variants for the tumor-binding antibody
B72.3. Protein Engineering 7(8),1027-1033.

69

33. DiScipio, R.G. and Davie, E.W. (1979). Characterization of Protein S, a yCarboxyglutamic Acid Containing Protein from Bovine and Human Plasma.
Biochemistry, 18, 899-904.
34. DiScipio, R.G., Hermodson, M.A., Yates, S.G., and Davie, E.W. (1977). A
comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart
factor), and protein S. Biochemistry 16, 698-706.
35. Dorland, I. and Newman W.A. (1988). Dorland's illustrated medical dictionary (27 th
ed). W.B Saounder's Company, Philadephia.
36. Dreyfus, M., Magny, J.F., Bridey, F., Schwarz, H.P., Planche, C., Dehan, M., and
Tchernia, G. (1991). Treatment of homozygous protein C deficiency and neonatal
purpura fulminans with a purified protein C concentrate. N. Engl. J Med. 325, 15651568.
37. Eli Lilly (2001). http://www.1illy.com/
38. Esmon, C.T. (1990). Regulation of coagulation: the nature of the problem. In: Protein
C and related anticoagulants. Bruley, D.F. and Drohan, W.N. (Ed.), 3-10, Gulf
Publishing, Houston.
39. Fasmon, G.D. (1989). Practical Handbook of Biochemistry and Molecular Biology.
CRC Press, Boca Raton, Florida, 265.
40. Foster, D.C., Yoshitake, S., and Davies, E.W. (1985). The nucleotide sequence of the
gene for human protein C. Proc. Nat!. Acad. Sci. USA 82,4673-4677.
41. Furie, B. and Furie, B.C. (1988). The Molecular Basis of Blood Coagulation. Cell 53,
505-518.
42. Goldhaber, S.Z. (1994). Epidemiology of pulmonary embolism and deep vein
thrombosis. In: Haemostasis and Thrombosis. Bloom, A.L., Frobes, C.D., Thomas,
D.P., and Tuddenham, E.G.D. (Ed.), 1327-1333, Churchill-Livingstone, London.
43. Griffin, 1.H., Kojima, K., Banka, C.L., Curtiss, L.K., and Fernandez, J.A. (1999).
High-density lipoprotein enhancement of anticoagulant activities of plasma protein S
and activated protein C. J. Cin. Invest. 103,219-227.
44. Griffiths, A.D., Malmqvist, M, Marks, J.D., Bye, 1.M., Embleton, MJ., McCafferty,
1., Baier, M., Holliger, K.P., Gorick, B.D., Hughes-Jones, N.C., Hoogenboom, H.R.,
and Winter, G. (1993). Human anti-self antibodies with high specificity from phage
display libraries. EMBO J. 12, 725-734.

70

45. Griffiths, A.D., Williams, S.C., Hartlet, 0., Tomlinson, I.M., Waterhouse, P., Crosby,
W.L., Kontermann, R.E., Jones, P.T., Low, N.L., Allison, l, Prospero, T.D.,
Hoogenboom, H.R., Nissim, A., Cox, lP.L., Harrison, lL., Zaccolo, M., Gherardi,
E., and Winter, G. (1994). Isolation of high affinity human antibodies directly from
large synthetic repertories, EMBO journal. 13(14),3245-3260.
46. Grinnell, B.W., Walls, lD., Gerlitz, B., Berg, D.T., McClure, D.B., Ehrlich, H. Bang,
N.U., and Van, S.B. (1990). Native and modified recombinant human protein C:
function, secretion, and posttranslational modifications. In: Protein C and related
anticoagulants. Bruley, D.F. and Drohan, W.N. (Ed.), 29-63, Gulf Publishing,
Houston.
47. Heijboer, H., Brandjes, D., BOller, H.R., Sturk, A., and Ten Cate, lW. (1990).
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with
deep-vein thrombosis. N. Eng. J Med. 323, 1512-1516.
48. Hirsh, J., Dalen, lE., Anderson, D.R., Poller, 1., Bussey, H., Ansell, J. Deyking, D.,
and Brandt, J.T. (1999a). Oral anticoagulants: mechanism of action, clinical
effectiveness, and optimal therapeutic range. Chest 114, 445S-469S.
49. Hirsh, J., Warkentin, T.E., Raschke, R., Granger, C., Ohman, E.M., and Dalen, lE.
(1999b). Heparin and low-molecular weight heparin: mechanisms of action,
pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 114,
489S-510S.
50. Hollinger, P., Prospero, T., and Winter, G. (1993). Proc. Natl Acad. Sci. USA, 90,
6444-6448.
51. Hopkins, T.R. (1991). Physical and chemical cell disruption for the recovery of
intracellular proteins. Bioprocess Technol. 12,57-83.
52. Hom, u., Strittmatter, W., Krebber, A., KnOpfer, u., Kujau, M., Wenderoth, R.,
MOller, K., Matzku, S., PlOckthun, A., and Riesenberg, D. (1996). High volumetric
yields of functional dimeric miniantibodies in Escherichia coli, using an optimized
expression vector and high-ceIl-density fermentation under non-limited growth
conditions. Appl. Microbiol. Biotechnol. 46, 524-532.
53. Imanaka, T., Kaieda, T., and Taguchi, H. (1973). Unsteady-state analysis of a kinetic
model for cell growth and a-galactosidase production in mold. J Ferment. Technol.,
51(6),423-430.
54. Jackson, C.M. (1994). Physiology and biochemistry of prothrombin. In: Haemostasis
and Thrombosis. Bloom, A.L., Frobes, C.D., Thomas, D.P., and Tuddenham, E.G.D.
(Eds.), 397-438, Churchill-Livingstone, London.

71

55. James, H.L. (1994). Physiology and biochemistry of factor X. In: Haemostasis and
Thrombosis. Bloom, AL., Frobes, C.D., Thomas, D.P., and Tuddenham, E.G.D.
(Eds.), 439-464, Churchill-Livingstone, London.
56. Josic, D., Hoffer, L., and Buchacher, A (2003). Preparation of vitamin K-dependent
proteins, such as clotting factors II, VII, IX and X and clotting inhibitor Protein C. J
Chromatogr. B, 790, 183-197.
57. Kang, K.A. (1991). Distributed nature of equilibrium in affinity chromatography:
mathematical modeling, simulation, and scale-up. Ph.D. Dissertation. Chemical
Engineering, University of California Davis, California.
58. Kang, K.A. and Ryu, D.D.Y. (1991). Studies on scale-up parameters of an
immunoglobulin separation system using protein-A affinity-chromatography.
Biotechnol. Prog. 7,205-212.
59. Kang, K.A, Ryu, D., Drohan, W.M., and Orthner, C.L. (1992). Effect of matrices on
affinity purification of protein C. Biotechnol. Bioeng. 39, 1086-1096.
60. Kemkes-Matthes, B. and Matthes, KJ. (1995). Protein Z deficiency: a new cause of
bleeding tendency. Thrombosis Research 79, 49-55.
61. Kempf, E., Weiss, E, Klein, P., Glacet, A., Spratt, S., Bourel, D., and Orfanoudakis,
G. (2001). The rescue by phage display of human Fabs to gp120 HIV-1 glycoprotein
using EBV transformed lymphocytes. Molecular Biotechnology 17, 97-108.
62. Kiefhaber, T., Rudolf, R., Kohler, H.-H., and Buchner, J. (1991). Protein aggregation
in vitro and in vivo: a quantitative model of the kinetic competition between folding
and aggregation. Bio/Technology 9, 825-829.
63. Kilikian, B.V., Suarez, J.D., Liria, C.W., and Gombert, A.K. (2000). Process
strategies to improve heterologous protein production in Escherichia coli under
lactose or IPTG induction. Process Biochemistry 35, 1019-1025.
64. Kipriyanov, S.M., Dubel, S., Breitling, F., Kontermann, R.E., and Little, M. (1994).
Recombinant single-chain Fv fragments carrying C-terminal cysteine residues:
production of bivalent and biotinylated miniantibodies. Mol. Immunol. 31, 1047.
65. Kipriyanov, S.M., Moldenhauer, G., and Little M. (1997). High level production of
soluble single chain antibodies in small-scale Escherichia coli cultures J of
Immunological Methods 200,69-77.
66. Kisiel, W. (1979). Human plasma protein C. J Clin. Invest. 64,761-769.

72

67. Kisiel, W., Canfield, W.M., Ericsson, L.H., and Davie, E.W. (1977). Anticoagulant
properties of bovine protein C following activation by thrombin. Biochemistry 16,
5824-31.
68. Korah, L.K. (2002). Development of Economical Production and Purification
Processes for the Mini-Antibody against Protein C. MS. Thesis. Chemical
Engineering, University of Louisville, Kentucky.
69. Korah, L.K. and Kang, K.A. (2003a). Preliminary Study for the Protein C Purification
Using Mini-Antibodies Produced from Recombinant E. coli. In: Oxygen Transport to
Tissue xxv. Thomiley, Harrison, and James, (Eds), 171-176, Kluwer
AcademiclPlenum Publishers, New York.
70. Korah, L.K., Ahn, D.G., and Kang, K.A. (2003b). Mini-antibody Production Process
for the Purification of Protein C. In: Oxygen Transport to Tissue XXIII. Wilson, D.F.,
Evans, S.M., Biaglow, J., and Pastuszko, A. (Eds.), 510, 127-132, Kluwer
AcademiclPlenum Publishers, New York.
71. Kuzel T.M. and Rosen S.T. (1994). Antibodies in the treatment of human cancer.
Curro Opinion Oncol. 6, 622-626.
72. Leytus, S.P., Foster, D.C., Kurachi, K., and Davie, E.W. (1986). Gene for Human
Factor X; A Blood Coagulation Factor Whose Gene Organization is Essentially
Identical with that of Factor IX and Protein C. Biochemistry 25, 5098-5102.
73. Linde-Zwirble, W.T., Angus, D.C., Carc illo , J., Lidicker, J., Clermont, G., and
Pinsky, M.R. (1999). Age-specific incidence and outcome of sepsis in the US. Crit
Care Med 27(Suppl 1), A33 abstract.
74. Lu, B., Smyth, M.R., and Kennedy, R.O. (1996). Oriented Immobilization of
Antibodies and Its Applications in Immunoassays and Immunosensors. Analyst 121,
29R-32R.
75. Makris, M., Rosendal, F.R., and Preston, F.E. (1997). Familial thrombophilia: genetic
risk factors and management. Journal Internal Medicine 242(Suppl 740), 9-15.
76. MaIm, J., Laurell, M., Nilsson, I.M., and Dahlback, B. (1992). Thromboembolic
disease-Critical evaluation oflaboratory investigation. Thromb. Haemost. 68, 7-13.
77. Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Griffiths, A.D., and
Winter, G. (1991). By-passing immunization. Human Antibodies from V-gene
Libraries Displayed on Phage. J Mol. Bioi. 222,581-597.
78. Marlar, R.A. and Neumann, A. (1990). Neonatal purpura fulminans due to
homozygous protein C or protein S deficiencies. Semin Thromb Hemost 16, 299-309.

73

79. Marlar, R.A., Kleiss, AJ., and Griffin, J.H. (1982). Mechanism of action of human
activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 59, 1067-72.
80. Marlar, R.A., Kleiss, A.1., and Griffin, J.H. (1981). Human protein C: Inactivation of
FactorV and Villin plasma by the activated molecule. Ann NY A cad Sci 370, 303.
81. McQuillan, A.M., Eikelboom, 1.W., Hankey, GJ., Baker, R., Thorn, 1., Staton, 1., Yi,
Q., and Cole, V. (2003). Protein Z in ischemic stroke and its etiologic subtypes.
Stroke 34, 2415-2419.
82. Miletich, J.P., Prescott, S.M., White, R., Majerus, P.W., and Bovill, E.G. (1993).
Inherited predisposition to thrombosis. Cell 72, 477-480.
83. Morbe, J.L. and Riesenberg, D. (1997). Release of miniantibodies from E. coli cells
into the supernatant at low and high cell densities. Microbiol. Res. 152,385-394.
84. Nakamura, S. and Sakata, Y. (1987). lmmunoaffinity purification of protein C by
using confromation-specific monoclonal antibodies to protein C-calcium ion
complex. Biochimica et Biophysica Acta 925, 85-93.
85. Nikaido, H. (1990). Permeability of the lipid domains of bacteria membranes. In:
Membrane transport and information storage. Advances in membrane fluidity. Aloja,
R.C., Curtain, C.C., and Gordon, L.M. (Eds), 165-190, Alan R. Liss Inc., New York.
86. Nissim, A., Hoogenboom, H.R., Tomlinson, I.M., Flynn, G., Midgley, C., Lane, D.,
and Winter, G. (1994). Antibody fragments from a 'single pot' phage display library
as immunochemical reagents. EMBO J., 13, 692-698.
87. Pack, P., Kujau, M., Schroeckh, V., KnUpfer, u., Wende roth, R., Riesenberg, D., and
PlUckthun, A. (1993). Improved bivalent miniantibodies, with identical avidity as
whole antibodies, produced by high cell density fermentation of Escherichia coli.
Biotechnol. 11, 1271-1277.
88. Porath J., Carlsson 1., Olsson I., and Belfrage G. (1975). Metal chelate affinity
chromatography, a new approach to protein fractionation. Nature 258,598-599.
89. Rangel-Frausto, M.S., Pittet, D., Costigan, M., Hwang, T., Davis, C.S., and Wenzel,
R.P. (1995). The natural history of the systemic inflammatory response syndrome
(SIRS): a prospective study. JAMA 273, 117-23.
90. Rousch, M., Lutgerink, J.T., Coote, 1., Bruine, A.d., Arends, 1.-W., and Hoogenboom,
H.R. (1998). Somatostatin displayed on filamentous phage as a receptor-specific
agonist. British Journal of Pharmacology 125, 5-16.

74

91. Reiner, A.P. and Davie, E.W. (1994). The physiology and biochemistry of factor IX.
In: Haemostasis and Thrombosis. Bloom, A.L., Frobes, C.D., Thomas, D.P., and
Tuddenham, E.G.D. (Eds.), 309-331, Churchill-Livingstone, London.
92. Rezania, S., Ahn, D.G., and Kang, K.A (2005). Cost Effective Metal Affinity
Chromatography for Protein C Specific Mini-Antibody Purification. Proceeding of
2004 Annual ISOTT Meeting (accepted)

93. Schoppmann, A., Weber, A., Nicolic N., Polsler, G., Varadi, K., and Turecek, P.L.
(2001). Ceprotin - a highly purified protein C concentrate: product characterization.
XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris.
94. Schwarz, H.P., Schramm, W., and Dreyfus, M. (1990). Monoclonal antibody purified
protein C concentrate: initial clinical experience. In: Protein C and related
anticoagulants. Bruley, D.F. and Drohan, W.N. (Eds). 83-89, Gulf Publishing,
Houston.
95. Soria, J., Samama, M., Nicolas, G., and Kisiel, W. (1985). Severe protein C
deficiency in congenital thrombotic disease-description of an immunoenzymological
assay for protein C determination. Thrombosis and Haemostasis 53, 293-296.
96. Stenfio, l (1976). A new vitamin K-dependent protein: purification from bovine
plasma and prelininary characterization. J. Bioi. Chem. 251,355-63.
97. Sterogene Bioseparations, Inc. http://www.sterogene.com
98. Suzuki, K., Moriguchi, A., Nagayoshi, A., Mutoh, S., Katsuki, S., and Hashimoto, S.
(1985). Enzyme immunoassay of human protein C by using monoclonal antibodies.
Thrombosis Research 38, 611-621.
99. Tabernero, M.D., Tomas, IF., Alberca, 1., Orfao, A., Borrasca, A.L., and Vicente, V.
(1991). Incidence and clinical characteristics of hereditary disorders associated with
venous thrombosis. Am. J. Hematol. 36, 249-254.
100. Tomokiyo, K., Yano, H., Imamura, M., Nakano, Y., Nakagaki, T., Ogata, Y.,
Terano, T., Miyamoto, S., and Funatsu, A. (2003). Large-scale production and
properties of human plasma-derived activated Factor VII concentrate. Vox Sanguinis
84,54-64.
101. van Sommeren, A.P.G., Machielsen, P.A.G.M., and Gribnau, T.C.J. (1993).
Comparison of three activated agaroses for use in affinity chromatography: effects on
coupling performance and ligand leakage. J. Chromatogra. 369,23-31.

75

102. Vazquez-Lopez, C., de Armas-Serra, C., Gimenez-Pardo, C., and RodriguezCaabeiro, F. (1999). Proteolytic activity of the Gymnorhynchus gigas plerocercoid:
purification and properties of a collagenase from the crude extract. Parasitol Res. 85,
64-70.
103. Velander, W.H., Morcol, T., Clark, D.B., Gee, D., and Drohan, W.N. (1990).
Technological challenges for large-scale purification of protein C. In: Protein C and
related anticoagulants. Bruley, D.F. and Drohan, W.N. (Eds). 11-27, Gulf Publishing,
Houston.
104. Velander, W.H., Johnson, 1.L., Page, R.L., Russell, L.G., Subramanian, A., Wilkins,
T.D., Gwazdauskas, F.C., Pittius, C., and Drohan, C.V.N. (1992). High level
expression in the milk of transgenic: swine using the cDNA encoding human protein
C. Proc. Nat!. Acad. Sci. USA 89, 12003-12007.
105. Whitlow, M., Bell, B. A., Feng, S.-L., Filpula, D., Hardman, K. D., Hubert, S. L.,
Rollence, M. L., Wood, J. F., Schott, M. E., Milenic, D. E., Yokota, T., and Schlom,
1. (1993). An improved linker for single-chain Fv with reduced aggregation and
enhanced proteolytic stability. Protein Engineering. 6 (8),989-995.
106. Whitlow, M. and Filpula, D. (1991). Single-chain Fv proteins and their fusion
proteins.Methods, a Companion to Alethods in Enzymology 2,97.
107. Wilkinson, D. (2000). Immunochemical techniques inspire development of new
antibody purification methods. The Scientist 14(8), 25.
108. Wu, H. and Bruley, D.F. (1999). Homologous human blood protein separation using
immobilized metal affinity chromatography-protein C separation from prothrombin
with application of the separation of factor IX and prothrombin, Biotechnol. Prog.
15(5), 928-931.
109. Wu, H., Bruley, D.F., and Kang, K.A. (1998a). Protein C separation from human
blood plasma Cohn Fraction IV -1 using immobilized metal affinity chromatography.
In: Oxygen Transport to Tissue XX. Hudetz, A.G. and Bruley, D.F. (Eds). 454, 697705, Plenum Press, New York.
110. Wu, H. (2000a). Protein separation from homologous human blood proteins, Cohn
fraction IV -1 using immobilized metal affinity chromatography. Ph.D. Dissertation.
Chemical and Biochemical Enginet::ring, University of Maryland Baltimore County,
Maryland.
111. Wu, H. (2000b). Personal communication.

76

112. Wu, H., Goud, G.N., and Sierks, M.R. (1998b). Artificial antibodies for affinity
chromatography of homologous proteins: application to blood clotting proteins,
Biotechnol. Prog. 14, 496-499.
113. Yoshitake, S., Schach, B.G., Foster, D.C., Davies, E.W., and Kurachi, K. (1985).
Nucleotide Sequence of the Gene f()r Human Factor IX (Antithemophilic Factor B).
Biochemistry 24, 3736-3750.

77

NOMENCLATURE

aPC: Activated Protein C
BCA: Bicinchoninic Acid
BSA: Bovine Serum Albumin
CNBr: Cyanogen bromide
DEAE: Diethylaminoethyl

DI water: Deionized Water
DMEM: Dulbecco's Modification of Eagle's Medium
E. coli: Escherichia coli
ELISA: Enzyme Linked Immunosorbent Assay
FII: human blood factor II
FVII: human blood factor VII
FIX: human blood factor IX
FX: human blood factor X
FDA: Food and Drug Administration
Fv: Variable Fragment
HIT: heparin induced thrombocytopenia
HRP: Horseradish Peroxidase
HSA: Human Serum Albumin
ICUs: Intensive Care Units
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IDA: Iminodiacetic Acid
IgG: Immunoglobulin G
IMAC: Immobilized Metal Affinity Chromatography
IPTG: Isopropyl P-D-thiogalactopyranoside
LPS: Lipopolysaccharides
Mab: Monoclonal Antibody
Mini-Mab: Mini-Antibody
MW: Molecular Weight
NHS: Normal Hydroxysuccinimide
NTA: Nitrilotriacetic acid
O.D.: Optical Density
OPD: O-phenylenediamine Dichloride
PC: Protein C
PCC: Prothrombin complex concentrate
PEG: Polyethylene Glycol
pI: Isoelectric point
PMSF: Phenylmethylsulfonyl Fluoride
rhPC: Recombinant Human PC
scFv: Single-chain Variable Fragment
SDS-P AGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
TBS: Tris Buffered Saline
TBST: Tris Buffered Saline with Tween 20
TEMED: Tetrameth yleth yl enediamine
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V H: Variable Region in a Heavy Chain
VL: Variable Region in a Light chain
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